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Abstract 
The human mesoderm induction early response gene 1 (hmier 1) is a growth factor 
induced gene encoding a novel transcription factor. There are two major isoforms of 
hMIERl, hMIERla and hMIER1p, which differ in their C-terrnini (Patemo et al., 2002). 
In pat1icular, hMIERI a, but not hMIER 1 p, contains a conserved motif important for 
interaction with nuclear hormone receptors, the LXXLL motif. Further analysis revealed 
that hMIERl was differentially expressed in normal human breast compared to breast 
carcinoma cell lines and tissues, implying it may have a role in the neoplastic state 
(Paterno et al., 1998; Paterno et al., 2002). 
In th is study, the role ofhMIERl as a coregulator of the estrogen receptor (ER) 
was investigated. The physiological effects of estrogen are mediated by two receptors: 
estrogen receptor alpha (ERa) and estrogen receptor beta (ERp). It has previously been 
shown that both ERa and ERP interact with hMIERla and hMIER1P in vitro (Fifield, 
Honours dissettation). Electrophoretic mobility shift assays (EMSAs) were perfom1ed to 
detetmine if hMIER I a or hMIER 1 p interaction with ERa or ERP affected the abi I i ty of 
the ER to bind a consensus ERE in the absence and presence of specific ligands. These 
studies revealed that hMIERla inhibited DNA binding ofboth ER subtypes in the 
absence or presence of ligand. In contrast, hMIER 1 p inhibited the DNA binding of the 
ERP in presence and absence of ligand, but has little effect on the DNA binding of ERa. 
Further studies were performed to determine if the in vitro interaction and effect 
on DNA binding would be translated into functional effects in vivo. Experiments in HEK 
293 cells showed that in the absence of ligand, hMIERl a and hMIER 1 P enhanced ERE-
- -- - - --- --- -
driven transcription with the ERa, but not ER~ . In the presence of I igand, such as 
estrogen or the ERa-specific agonist, propylpryazole-triol (PPT), neither hMIERl a nor 
hMIERl ~significantly affected ERE-driven transcription with ERa ln the presence of 
diarylpropionitrile (DPN), an ER~ specific agonist, neither hMIERla nor hMIERl~ 
affected ERE-driven transcription withER~ . 
Overall these results imply that hMIERl a and hMIERl ~are involved in ligand 
independent activation of ERa, but have no functional effect on the ER~. This ER 
subtype selectivity, along with activation of ER signalling in the absence of estrogen or 
other ligands, warrant further investigation of the role that hMIERl plays in estrogen 
receptor signalling. 
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1. Introduction 
1 .1 General Introduction 
1.1.1 DNA and Cell Proliferation 
Deoxyribonucleic acid (DNA) is a complex macromolecule that serves as a 
canier of genetic information in all cells. The infom1ation canied in DNA is essential for 
organization, function and behaviour of most living cells. Genes are distinct functional 
units within the DNA that are the basis of hereditary characteristics. Genes provide the 
method through which DNA conveys infom1ation within the cell, as well as between 
generations. 
Nonnal cells are capable of replicating their DNA and passing it on to daughter 
cells in a series of events known as the cell cycle. A key event in cell division is the 
replication of DNA, which occurs during S phase. In order for the information stored in 
D A to be successfully passed through generations, DNA must be replicated accurately 
and any damage to the DNA must be detected and repaired. The cell machinery is 
capable of recogniz ing alterations in the DNA and arresting the cell cycle at various 
checkpoints during G 1, S, G2, or M phase to repair the DNA. Fai lure to recogni ze and 
repair DNA mutations can result in abnormal cell growth or development lead ing to 
many life threatening diseases. For example, cancer is often the result of mutations in cell 
cycle control genes. This disrupts nonnal cell growth control mechanisms and while 
impaired cell proliferation control is not the only contributing factor in cancer, it is a 
fundamental underlying feature. 
--------------------------------
1.1.2 DNA Packaging 
The amount of DNA that a cell must accommodate is extremely large, even in 
organisms that have relatively small genomes. DNA must be efficiently packaged but still 
be accessible to the cell machinery for replication and information signalling. In 
eukaryotic cells, DNA packaging is quite complex. In a non-dividing cell, the DNA is 
packaged with proteins as chromatin fibres dispersed throughout the nucleus. The 
proteins which play an important ro le in chromatin structure are known as histones. 
These proteins have a strong positive charge allowing them to bind to negatively charged 
DNA. Histones impose a repeating structural organization upon DNA that causes the 
chromatin to resemb le 'beads on a string'. As the cell gets ready to divide, the chromatin 
fibres condense and fold to form compact stmctures known as chromosomes. 
The regulation of chromatin and its structure controls important nuclear processes 
such as DNA transcription, replication, repair, mitosis and apoptosis (Hodawadekar and 
Mam1orstei n, 2007). Chromatin structure regulates the availability of DNA to cellular 
processing and is the basis for the differential expression of genes (reviewed in Gal-Yam 
et al., 2007). For example, DNA methylation in the mammalian genome is the addition of 
a methyl group to cytosine residues followed by guanine residues, known as CpG 
dinucleotides. Regions of the DNA with high cytosine-guanine dinucleoutide content are 
called CpG islands. These usually occur in the 5 ' regulatory region of genes; in fact many 
promoters are embedded in the CpG islands. These regions, unlike the CpG 
dinucleotides, are usually unmethylated and methylation often results in long tem1 gene 
repression. 
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Another type of DNA processing is histone modification, histones normally 
undergo many post translational modifications that result in changes in chromatin 
structure, gene expression, and DNA repair. In order for genes to be actively expressing 
infom1ation, they must be available to the cell machinery. In the compacted form of 
clu·omatin this is difficult, requiring changes in histone structure. One mechanism of 
altering histone structure is through acetylation, which is the addition of an acetyl group 
to specific lysine residues within the N-tem1inal tail of histone molecu les (Hodawadekar 
and Marmorstein, 2007). Histone acetyltransferases (HATs) are enzym es that function to 
add acetyl groups to histones, and this acetylation facilitates the access of transcriptional 
machinery to the gene promoters by loosening the packing of nucleosomes. Histone 
deacetylase (HDAC) proteins catalyze the removal of acetyl groups from histone 
proteins, resulting in a chromatin structure that is unavailable to the transcriptional 
machinery and susequent repression of gene expression. 
1.1.3 Transcription 
The flow of information in cells proceeds from DNA to ribonucleic acid (RNA) to 
prote in . The genes encoded in DNA work as a template for the synthesis of RNA in a 
process called transcription (Becker et a!., 2003). Like DNA, RNA is made up of 
nucleotide subunits; RNA copied from DNA that encodes for protein is known as 
messenger RNA or mRNA. In eukaryotic cells, there are three enzymes that are involved 
in transcription, RNA polym erase I, II, and III. RNA polymerase II are the enzymes that 
transcribe the genes that code for mRNA to be translated into protein. RNA polymerase 
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II binds and locally unwinds the DNA double helix to allow the initiation of mRNA 
synthesis. This enzyme is responsible for the four stages of transcription; binding, 
initiation, elongation and termination. 
RNA polymerase binds to a specific region of the gene known as the promoter; 
this site determines where RNA synthesis starts and which DNA strand is to serve as the 
template. Binding of the R A polymerase to DNA requires the participation of addi tional 
proteins known as transcription factors. Transcription factors that are required for an 
RNA polymerase molecule to bind its promoter sequence and initiate transcription, 
regardless of the specific gene, are known as general transcription factors. Many genes 
have short DNA sequences outside the core promoter to which other, more specific, 
transcription factors bind and affect transcription. These are known as regulatory 
transcription factors and upon binding, their specific DNA elements can recruit 
coactivator or corepressor proteins to control the gene expression in a cell in response to 
the environmental and physiological conditions. 
1. 1.4 Cell proliferation and Cancer 
The development, differentiation, and growth of cells in a multicellular organism 
must be under tight control to ensure the needs of the organism are met. Cancer is an 
example of what happens when cell proliferation continues unabated, and often results 
from errors in cell cyc le and transcriptional control mechanisms. 
DNA mutations occur spontaneously, but can also be the result of mutagens in the 
environment. If these mutations are not repaired, accumulation of multiple lesions can 
4 
cause a ce ll to become cancerous. Proto-oncogenes are nom1al cellular genes that code 
for proteins that regu late cell growth and differentiation. If mutated, these regu latory 
genes have the potential to become oncogenes, which in turn may promote tumour 
growth . Most oncogenes code for components or regulators of growth factor signall ing 
pathways such as growth factors, receptors, or transcription factors . 
1.2 Nuclear Hormone Receptors 
1.2.1 Structure 
Nuclear hom1one receptors are a family of receptors which are targets for lipid 
soluble molecules such as steroid hormones (reviewed in Singh and Kumar, 2005). These 
receptors, unlike membrane bound receptors, are intracell ular and capable of directly 
affecting their target genes. The activation of these genes results in regulation of many 
physiological functions, including growth and development. Dysregu lation of the 
receptors and their target genes leads to the development of many types of cancer and 
other serious diseases such as diabetes. 
Nuclear hormone receptors share a common structure that consists of three 
independent functional regions (Figure l) (reviewed in Nilsson et al., 200 1). The first is 
the AlB domain at the N-tenninus, which encodes the ligand independent activation 
function domain (AF-1). This region of the receptor is involved in protein-protein 
interactions as well as transcriptional activation of target gene expression. Adjacent to the 
AlB domain is the DNA binding or C domain, this is important for binding of the 
receptor to specific DNA sequences called hormone response elements (HRE's) and 
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contains the first of two interfaces important in receptor dimerization. The last functional 
domain is the ligand binding orE domain. This domain contains a receptor dimerization 
interface, it mediates ligand binding, nuclear translocation and transactivation of target 
gene sequences. This region also contains a second activation function domain (AF-2) 
which is the ligand-dependant transcriptional activation domain. The F domain at the 
carboxy terminus of the ER is a variable region, whose specific function is currently 
unknown (reviewed in Hanstein et al., 2004) Linking the C domain to the E/F domain is 
the D region or hinge region . The D region is poorly characterized and not well 
conserved between different nuclear hormone receptors. It has been shown to be 
associated with molecular chaperone proteins such as heat shock protein 90 (hsp90) 
(reviewed in Pettersson & Gustafsson, 2001). 
1.2.2 Model of Steroid Nuclear Receptor Action 
Steroid honnone receptors are a subset of the nuclear hormone receptor family 
that interact with small hydrophobic ligands capable of regulating growth, differentiation, 
and homeostasis in eukaryotic cells (reviewed in Hanstein et al. , 2004). This class of 
nuclear honnone receptors are transcription factors whose activity is regulated by ligand 
binding. Using the estrogen receptor (ER) as an example, it is possible to examine how 
these receptors can function through several specific mechanisms; namely the ligand-
dependent classical or non-classical pathways, and the ligand-independent pathway. 
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ERa 
ERp 
N-1 AlB 
N-1 AlB 
AF-1 
DNA binding domain (DBD) 
Hinge Region 
Ligand binding domain (LBO) 
c 
c 
I D I E I F 1-c 
I D I E I F l-c 
AF-2 
Figure 1: Domain structure of Steroid Nuclear Hormone Receptors ERa and ERP 
Schematic representation of the ERa. and ER~. At theN terminus is the AlB domain 
which contains an acidic activation domain important for ligand-independent 
transactivation (AF-1). Adjacent to the AlB domain is the DNA binding domain or C 
domain. This portion of the receptor is essential for recognition of specific estrogen 
response elements (EREs). The C domain is linked to the ligand binding domain, or E 
domain, by a hinge region or D domain. The E domain contains a second activation 
domain responsible for ligand-dependent transcriptional activation (AF-2). The F domain 
is a variable region. 
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A. Classical Pathway 
ERE 
B. T~ Factor Crosstalc Pathway 
ERE 
C Ligand Independent Pathway 
• Growth Factor y Growth factornteeplor 
ERE 
Cel~ne 
() MAPkinases 
AlP \....,_ 
AOP ~ 
Figure 2: Ligand dependent classical (A), non-classical (B) and ligand independent 
(C) models of estrogen receptor activation. 
A. Classical model of estrogen receptor activation begins with binding of ligand (E2). 
The receptor then forms homo or heterodimers and translocates to the nucleus of the cell, 
where it binds to its specific hormone response element and activates transcription 
through recruitment of coactivator complexes. 
B. Non-Classical model of estrogen activation also begins with ligand binding, 
dimerization and translocation to the nucleus. In the non-classical model the ER does not 
bind DNA directly but is recruited to another DNA bound transcription factor such as 
Sp I or AP-I. The receptor then enhances transcription through association with 
coactivator complexes. 
C. Ligand independent model of estrogen receptor activation occurs in the absence of a 
typical ligand such as E2. The pathway is usually activated by the binding of a peptide 
growth factor to its membrane associated receptor. This results in a signalling cascade 
that results phosphorylation of the ER by specific kinases. The phosphorylated form of 
the ER is activated, binds the hormone response element and enhances transcription 
through the association with coactivator complexes. 
[Adapted from Nilsson et aL, 200 I , and Heldring et aL, 2007] 
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activation w ithout ER directly binding DNA. ER also interacts with the fos/jun 
transcription factor complex on API sites to stimulate gene expression (reviewed in 
Kushner et al. , 2000). Agonist bound ERa enl1ances AP 1 activity via interaction with the 
p 160 family of coactivators whereas antagonist boundER~ also enllances AP !-dependent 
transcription by sequestering corepressors away from the API complex. C. Ligand-
independent model. The fact that ER activity was observed in the absence of estrogen 
challenged the view ofER as a ligand-dependent transcription factor. In the ligand-
independent model, peptide growth factors, protein kinase A (PKA) activating factors , 
and cyclins can induce ER mediated activity in the absence ofER-specific li gands 
(reviewed in Pettersson and Gustafsson, 2001). The N-tenninus of the ER contains 
several conserved serine residues that are targets for phosphorylation. In the absence of 
ligand, growth factor signalling leads to the activation of kinases that phosphorylate and 
activate the ER or its associated coregulators (reviewed in Heldring eta!., 2007). For 
example, epidermal growth factor (EGF) is a peptide growth factor that can mimic the 
effects of estrogen through the ER. EGF binds its membrane-bound receptor/tyrosine 
kinase, which in turn activates a mitogen-activated protein kinase (MAPK) signalling 
cascade. MAPKs phosphorylates the ERin the AF-1 domain resulting in an activated ER 
that can then proceed through the classical or non classical models of activation. 
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1.3 The Estrogen Receptor 
1.3.1 Estrogen Receptor: ERa and ER~ 
It was discovered, based on the binding of 1 7-~-estradiol (E2) in the uterus, that 
the biological effects of the steroid hormone estrogen were mediated by a nuclear 
hormone receptor labelled the estrogen receptor (ER). This receptor was believed to be 
the single mediator of the physiological effects of estrogen until 1996, when a novel 
estrogen receptor was discovered in the rat prostate (Kuiper eta!., 1996). To distinguish 
the two receptors, the original estrogen receptor was re-named ERa and the new second 
receptor was designated ER~. ERa and ERP are not splice variants from the same gene 
but rather distinct products of different genes on separate chromosomes (reviewed in 
Matthews and Gustafsson, 2003). The ER isoforms belong to the family of nuclear 
hormone receptors and thus contain highly conserved structure. The DNA binding 
domains ofthe two receptors are almost identical, displaying 97% sequence similarity 
(reviewed in Pettersson and Gustafsson, 2001 ). The li gand binding domain is the least 
well conserved between the two isoforms with an overall amino acid identity of 55%, 
however specific regions involved in ligand binding and the AF-2 display a higher 
sequence similarity. The main difference between the receptor subtypes is in the affinity 
for various selective estrogen receptor modulator compounds (SERMs) and the 
transcriptional response elicited by these compounds. 
Ra and ERP are both capable of binding estrogen and have simi lar binding 
specificities. Both receptor subtypes produce genomic and non-genomic effects in 
response to estrogen (reviewed in Singh and Kumar, 2005). The non-genomic effects are 
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rapid responses within the cytoplasm that are mainly due to the activation of various 
protein kinase cascades. However, this study is focused on the different effects of the 
receptor subtypes at the genomic level. 
Recently, there has been evidence that the presence of ER~ in cells that also 
express ERa results in a distinct profile of gene expression compared to cells expressing 
only ERa or ER~ (Chang et al., 2006; Williams et al., 2007). In the absence of estrogen 
stimulation, ER~ regulate genes that are normally regulated by ERa with estrogen (Chang 
et al., 2006). In the presence of estrogen, ER~ also stimulates the expression of a unique 
subset of genes that are not regulated by ERa alone. Many of the genes modulated by 
ER~ are those involved in cell cycle progression and apoptotic mechanisms. Recent 
studies have shown that ER~ inhibits the expression of ERa-regulated genes and is also 
capable of opposing ERa-E2 induced proliferation (Williams et al., 2007). This provides 
evidence that ER~ may have a protective effect from the proliferative response elicited by 
the ERa in the presence of estrogen. The relative levels of ERa and ER~ in normal and 
abnom1al breast tissue is an imporiant issue in determining how the cells will respond to 
different endocrine therapies. 
When ERa and ER~ are co-expressed in a cell, they do not merely function as 
separate homodimers at the ERE, it has been shown that ERa and ER~ are capable of 
forming heterodimers (denoted ERa/~ in this text) and these heterodimers are capable of 
binding EREs (Cowely et al., 1997; Pace et al., 1997). Upon DNA binding, the ERa/~ 
heterodimer is also capable of recruiting ER cofactors and stimulating ERE-driven 
transcription. As homodimers, the ER subtypes clearly exhibit differential effects in the 
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response to estrogen and the effects on transcription from a consensus ERE (reviewed in 
Nilsson eta!., 2001). The function of the heterodimer, in nom1al and abnormal cell 
proliferation is currently unknown. 
1.3 .2 Coregulators of the Estrogen Receptor 
The ER is not solely responsible for mediating the effects of estrogen; upon DNA 
binding the ER recruits other proteins known as coregulators to form large multi protein 
complexes. It is through the interaction with coregulators that chromatin remodelling, 
histone modification, transcription initiation elongation, splicing or terminal degradation 
occurs (reviewed in Moggs and Orphanides, 2001 ). Coregulators are critical for proper 
function of the ER and its effects on development, physiology and reproduction. These 
proteins are classified based on their effects on the transcriptional activity ofER, as 
coactivators, corepressors or cointegrators. It is important to note that these proteins do 
not function exclusively of one another, coactivators and corepressors may be found in 
the same large multifunctional protein complex despite their opposing action (reviewed 
in Pettersson and Gustafsson, 2001). 
Well characterized examples ofER coactivators are the members of the p160 or 
steroid receptor coactivator, SRC, family. These cofactors contain three of the LXXLL 
motifs typically found in ER cofactors, where Lis leucine and X is any amino acid (Ding 
et al., 1998). SRC-1 mediates functional interactions between the AF-1 and AF-2 domain 
resulting in AF domain synergy. The SRC-3 member of this family exhibits ER subtype 
selectivity, with a higher affinity and activation with ERa over ER~ (Suen et al., 1998). 
13 
SRC proteins also mediate interactions with cointegrator proteins such as p300 fam ily 
members. 
p300 and Creb-binding protein (CBP) have been characterized as a coactivators 
of many factors such as nuclear receptors, p53, and nuclear facto r NF-KB (reviewed in 
Petersson and Gustafsson, 2001). These coactivators possess intrinsic HAT activity, and 
are capable of acting synergistically with ligand-bound ER to enhance transcription . CBP 
interacts with both SRC-1 and the ER and the ER/SRC-1/CBP complex forms a stable 
ternary structure for coactivation of the ER (Hanstien et al., 1996). 
There are a variety of proteins that repress transcriptional activity of the ER. The most 
extensively studied corepressors include nuclear receptor corepressor (NCOR), and 
silencing mediator of retinoid and thyroid receptors (SMRT) (reviewed in Hall and 
McDonnell , 2005). These corepressors interact with ER and other nuclear receptors 
through a specific domain known as the CoRNR box, which contains sequences similar 
to that of the LXXLL domain found in nuclear receptor coactivators. NCOR and SMRT 
have both been found to associate with ERa in the presence of an antagonist such as 
tamoxifen (Smith et al., 1997; Lavinsky et al., 1998). In contrast, ERP has been found to 
bind NCOR and SMRT in the presence of agonists, but not antagonists, via the LXXLL-
Iike motif box (Webb et al., 2003). Differences in cofactor recruitment may be the basis 
for alternative function of the two ER isofom1s. 
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1.3.3 Estrogen Receptor in Breast Development 
Estrogen plays a key role in development and morphogenesis of reproductive 
tissues (reviewed in Pettersson and Gustafsson, 2001). The two subtypes ofER mediate 
the effect of estrogen on its target tissues and play distinct non-redundant roles in nom1al 
development and maintenance of tissues in the reproductive, immune, skeletal, 
cardiovascular, and central nervous systems. ERa and ER~ bind estrogen with relatively 
similar affinity, but differ in the response elicited at the promoter region of estrogen 
responsive genes. The proliferative effects of estrogen on many systems in the body 
appear to be the result of a fine balance between ERa and ER~ signalling. Extensive 
studies have been conducted on the role that the ER subtypes and their relative levels 
play in breast development and growth. 
Studies conducted in mice have provided much insight into the role of ERa and 
ER~ in the breast. In the adult mouse mammary gland, ER~ is expressed in over 60% of 
the ductal epithelial cells while ERa is only expressed in approximately 20% of the cells 
in the same gland. Also, ER~, but not ERa, is expressed in the stroma of the adult gland 
(reviewed in Held ring et al., 2007). It is interesting to note that in a developing 2 week 
o ld mouse embryo ERa and ER~ are both strongly expressed in the ductal epithelium and 
stroma. ERa-/- knockout mice demonstrate limited mammary growth even in the 
presence of estrogen (Kenney et al., 2003). When an ERa-/- mammary fat pad of a 3 
week old mouse is transplanted into the mammary fat pad of a wild type 3 week old 
mouse, ductal growth fails to occur around the ERa-/- implant, suggesting that it is 
secreting growth inhibitory substances. Since ER~ is still highly expressed in the 3 week 
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old mouse this suggests that ER~ stimulates secretion of a growth repressor such as 
transforming growth factor~ (TGF-~) (reviewed in Heldring et al., 2007). ER~ -/-
knockout studies suggest that it also has an important role in growth regulation and 
differentiation ofthe mammary epithelium. In fact, the ER~ -/-knockout mice show 
incomplete differentiation of mammary epithelium and as the mice age the gland 
continues to proliferate abnormally and fills with large cysts. This implies that loss of 
ER~ also leads to loss of mammary gland growth repression mechanisms. Other murine 
studies imply that ER~ may also play a role in the organization and adhesion of epitheli al 
cells and, therefore, affect differentiated tissue morphology (Forster eta!. , 2002). 
1.3.3 Selective Estrogen Receptor Modulators 
Compounds known as selective estrogen receptor modulators (SERMs) 
demonstrate remarkable differences in effectiveness and tissue selective action in 
response to estrogens. SERMs are tissue selective, functioning as agonists in some tissues 
while simultaneously acting as antagonists in other tissues. The discovery of ER~ led to a 
possible mechanism by which SERMs may produce tissue selective responses (reviewed 
in Katzenellenbogen and Katzenellenbogen, 2000). As previously discussed, ERa and 
ER~ are highly conserved and the majority of the differences between the two subtypes is 
in the ligand binding domain. This difference presents the possibility for some 
compounds such as steroids, phytoestrogens or androgen-derived diols to have affinity 
and potency preference for either ERa or ER~ . The response at any given target gene 
may vary based on the ER subtype or nature of its ligand (McDonnell, 1999). As a result 
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ERa and ER~ specific agonists and antagonists have been developed. In the case of ERa 
it has been discovered that a compound propypryazole-triol (PPT) (Figure 3) has over 
400-fold higher affinity for and is approximately 1000-fold more potent with ERa than 
withER~ as an agonist (Stauffer eta!., 2000). Similarly, methyl-pieridinopyrazole (MPP) 
is an antagonistic pyrazole compound that demonstrates approximately a 200-fold 
binding affinity for ERa (Sun eta!. , 2002). ER~ subtype specific ligands have also been 
discovered, for example the non-steroidal estrogen diarylpropionitrile (DPN) is an ER~ 
specific agonist with approximately 30-fold higher affinity for ER~ over ERa (Sun et 
a/. ,2003). ER~-specific antagonists include compounds such as R,R-terahydrohrysene 
(Meyers eta!., 2001) and mifipristone (Escande et al., 2006) . Further understanding and 
development ofER subtype specific ligands and their pharmacology is an important tool 
to discovering the exact function of each ER subtype and the role they play in estrogen-
related diseases. 
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Figure 3: Structure of estrogen receptor selective ligands Estradiol, PPT and DPN. 
Estradiol is a natural estrogen that has similar binding affinity with both ERa and ER~. 
Propypryazole-triol (PPT) is a synthesized ERa specific ligand, which has over 400 fold 
higher affinity for ERa over ER~. Diarylpropionitrile (DPN) is a synthesized ER~ 
specific agonist that has a 30 fold higher affinity for the ER~ subtype. 
[Reproduced from Harrington et al., 2003; Marino et al. , 2005] 
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1.3.4 Estrogen Receptor in Cancer 
Due to the ability of ERa and ER~ to differentially regulate estrogen-mediated 
growth and development ofthe breast, much focus has been placed on characterizing the 
mechanisms by which the ER subtypes affect breast cancer. Estrogen controls cell growth 
and differentiation through the ERin nom1al tissues and hormone responsive tumours 
through its ability to interact with specific ERE elements in estrogen-responsive genes 
and subsequently regulate transcription. For example, the ability to induce the expression 
of c-myc and cyclin D is responsible for much of the estrogen-regulated progression 
through the cell cycle (Doisneau-Sixou et al., 2003). 
Overexpression or hyperactivity ofER can result in an increase in cell cycle 
progression and enhanced tumour growth. However, the exact mechanism through which 
the ER functions in the proliferation of breast cells in response to estrogen is not full y 
understood . In normal murine mammary gland, proliferating ductal epithelial cells do not 
express ERa, indicating that E2 mediates its effects indirectly (reviewed in Petersson and 
Gustafsson, 2001 ). Yet in ERa expressing breast cancers, the effect of estrogen appears to 
occur directly through the ERa as it is blocked via treatment with the anti-estrogen 
tamoxifen which targets ERa. It is proposed that ERa may mediate breast growth 
indirectly by increasing growth factor secretion, but this does not explain why normal 
ERa-expressing mammary cells do not proliferate in response to estrogen but do so in 
breast cancer. This suggests that ER~ might play an important role in growth factor 
regulation and a fine balance of ERa and ER~ is necessary to maintain normal mammary 
growth. 
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ln human breast cancer, the evaluation of the role of the ERin pre-invasive 
mammary tumours is of particular interest (Roger et al., 2001). When cases of 
proliferating benign breast disease, non proliferating benign breast disease, and 
carcinoma in situ are compared, the percentage ofERP expressing cells was high in 
nom1al mammary glands and non-proliferating benign breast disease, but decreased 
significantly in proliferating benign breast disease and carcinoma in situ. The ERa 
showed an inverse expression when compared to ERP. As well, in a normal resting 
mammary gland, ERP is present in both luminal and myoepithelial cells whereas ERa is 
only found in some luminal epithelial cells. ERa shows a very different distribution and 
proportion which suggests a potentially protective effect of ERP against the mitogenic 
activity of estrogen. Some laboratories have reported a correlation between the presence 
of ERP and lower tumour stage and grade, as well as a predictive factor in the response to 
tamoxifen therapy in breast cancer (reviewed in Heldring et al., 2007; Hopp et al., 2004). 
However, these studies are widely debated and the potential ofERP as predicative factor 
or diagnostic marker in breast cancer is not clearly defined. 
1.4 MIER1 
1.4.1 MIERl: Structure 
Mesoderm Induction Early Response 1 gene or mier 1 was initially discovered in 
Xenopus laevis as a novel immediate early gene target of fibroblast growth factors (FGF) 
(Patemo et al. , 1997). FGFs are important for both embryonic and adu lt development. 
FGF plays an important role in cells derived from the middle embryonic layer of early 
embryos known as the mesoderm (Becker et al., 2003). The receptors for FGF are 
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receptor tyrosine kinases that upon phosphorylation activate a cascade of events that 
leads to cell proliferation and differentiation. This signal transduction is essential for 
proper development of many cell types such as muscle, cartilage, bone and blood. The 
first genes to be transcribed in response to such growth factor signalling are known as 
immediate early or early response genes. Many early response genes are transcription 
factors that are capable of enhancing or repressing the transcription of other genes. 
Early experiments with Xenopus mier 1 (xmier 1) showed that FGF treatment 
resulted in xmier 1 levels that were 3-4 fold higher than in non FGF treated controls 
(Paterno et al., 1997). To confirm that xmier 1 was an early response gene and that the 
expression was not dependent upon de novo protein synthesis, the expression was 
measured in the presence of a protein synthesis inhibitor, cycloheximide. xMIER 
expression was unaffected by the presence of cyclohximide, confim1ing that it is an early 
response gene. Further analysis of xmier 1 revealed that its product, xMIER I , had the 
potential for nuclear localization and contained stretches of acidic amino acids 
characteristic of acidic activation domains found in transcription factors (Paterno eta!., 
1997; Post eta!. , 2001). Upon further examination, it was determined that xMIERl was 
actually targeted to the nucleus and that the -tem1inus functioned as a potent activator 
of transcript ion. Combined, these resu lts support xmier 1 as an early response gene that 
codes for a novel transcription factor xMIER I . Since its discovery many studies have 
been conducted to further characterize the structure and function of mier 1. 
A human orthologue of xmierl, known as hmier1 displaying 91 % sequence 
simi larity was also discovered and characterized (Paterno et al., 1998; Paterno eta!., 
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2002). The structure of hmierl and its splice variants is shown in Figure 4. hmierl is a 
single copy gene consisting of 17 exons spanning 63 kb. Exon 3A functions as a skipped 
ex on and the last intron (intron 15) functions as a facultative intron. As a result of this, 
the single copy of hmierl ultimately gives rise to 6 predicted protein isoforms with 
common (exons 4-15) internal regions and varying N-terminal and C-terminal domains (a 
and p). The variation in the C-tenninal domain of the protein arises from alternative 
splicing of intron 15 at the 3' end of the gene. This, in tum, encodes two distinct C-
terminal domains, a and p. The a C-tem1inus results from the removal of intron 15 which 
encodes for a 23 amino acid C-domain. The~ C-terminus arises from the inclusion of 
intron 15, which encodes a larger 102 amino acid C-tenninal domain. The alternative C 
termini suggest alternative function and give rise to two dominant fotms of hMIER 1, 
hMJERla and hMIERI ~· 
The internal conserved region of hMIER 1 was found, upon comparison to other 
known proteins, to contain several conserved functional motifs as seen in Figure 5. This 
common region contains a highly acidic region, a proline rich motif, an ELM2 domain, 
and a signature SANT domain. The a and ~ isoforms also contain motifs specific to their 
differential splicing, a LXXLL motif and a nuclear localization signal (NLS), 
respectively. These domains provide indications as to the possible function of this novel 
protein. 
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A schematic of hmier 1 gene where the exons are shown in black, the introns as horizontal 
lines, the facultative intron is shown in grey and the white area represents the position of 
a and ~ c-terminal coding regions. A. Organization of the hmier 1 gene is shown with 
numbers below denoting the exons. B. An enlargement of the gene structure shown in A, 
demonstrating usage of promoter 2A or lB to produce distinct 5' ends. Also shown is the 
variation of the 3' end generated from alternative splicing, alternative promoter usage and 
alternative polyadenlyation signals (PAS). 
[Reproduced from Paterno et al., 2002] 
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hMIER1 a (1-433) N-
hMIER1p (1- 12) N-
Acidic activation domain 
I=:J ELM-2 domain 
SANTdomain 
c::J a C-terminus (LXXLL) 
p C-terminus (NLS) 
.. Conserved region containing PXXPP 
Figure 5: Structure of hMIERl isoforms 
LXXLL 
NLS 
Schematic illustration ofhMIERla (433 amino acids) and hMIER1~ (512 amino acids). 
Both isoforms contain several conserved motifs; at the N terminus there are four regions 
rich in acidic amino acids or an acidic activation domain, an ELM2 domain, a SANT 
domain and C terminal to the SANT domain is the PXXPP motif. hMIER1a and 
hMIER 1 ~ are distinct at their C termini, hMIER 1 a contains a LXXLL motif in this 
region whereas hMIERl ~contains a nuclear localization signal (NLS). 
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1.4.2 MIER 1 Functional Domains 
I. Acidic Activation Domain 
TheN tem1 inus ofxMIERI and hMIERl contains four stretches of highly acidic amino 
acids. These stretches correspond to a well characterized motif called the acidic 
activation domain that can be found in many transcription factors (reviewed in Struhl, 
1987). Acidic activation domains are particularly associated with transcriptional 
activation as they a id in the recruitment of transcriptional machinery (Melcher, 2000) . 
Constructs ofthe xMIERI protein revealed that while full length xMIERI did not 
activate transcription, a construct containing the four acidic stretches of theN tem1inal 
alone was capable of stimulating transcription (Patemo eta!., 1997). The deletion 
construct containing only the first three of the acidic stretches was a more potent 
transactivator that stimulated transcription 80 fold. This suggests that MIER l has the 
potential to function in activating transcription. Since hMIERl and xMIERl share 91 % 
sequence homology this suggests that the hMIERl acidic activation domain may also 
play a role in activation of transcription in human cells. 
II The ELM2 domain 
The ELM2 domain is also found in both forms of the hMIERl protein, and gets 
its name from the ~G1-27 and MTAI homology domain .f.. This domain was originally 
discovered in Caenorhabditis elegans protein EGL-27 and the human metastasis-
associated (MT A l) protein (Solari eta!., 1999). The EGL-27 protein was found to be 
very simi lar to MTAl with conserved functional domains ELMl and ELM2. EGL-27 is 
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important in developmental patteming of C. elegans, and MTA is a protein known to be 
part of a complex involved in transcriptional repression through the recruitment of 
HDAC (Wang eta!., 2006). In proteins containing ELM2 domains, it has been found that 
this domain plays an important role in recruitment ofHDAC activity (Ding eta!., 2003). 
In assays using a G5tkCAT reporter plasmid, which contains chloramphenicol 
acetyltransfease (CAT) linked to 5 GAL4 DNA binding sites and the thymidine kinase 
(tk) promoter, hMIER 1 a and hMIERl p both exhibit the ability to repress transcription . 
Further analysis showed the ELM2 domain ofhMIERl is essential for the binding of 
HDAC I and transcriptional repression. 
Ill The SANT domain 
The SANT domain was originally found in proteins SWI3, ADA2, N-CaR, and 
TFIIIB from which the name is derived (reviewed in Aasland eta!., 1996). SWI3 and 
ADA2 are components of either the SWI-SNF or ADA transcriptional acti vation 
complexes, N-CaR is a corepressor that regulates nuclear hormone receptors, and TFIIIB 
is the B subunit of the RNA polymerase III initiation complex. The function of the SANT 
domain is not fu lly understood; however it is highly related to the DNA binding domain 
of the MYB protein, containing 3 alpha helices in a helix-turn-helix motif. 
Recent studies have revealed that despite the similarity to the MYB DNA binding 
domain, the SANT domain contains hydrophobic residues in its recognition helix that are 
predicted to be incompatible with DNA binding (reviewed in Boyer eta!., 2004). It has 
been implied, therefore, that the SANT domain may play an essential role in regulation of 
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clu·omatin accessibility through protein-protein interactions. Additionally the SA T 
domain is essential for both HAT and HDAC activity. For example, in yeast the Ada2 is a 
conserved subunit in the GenS containing HAT complex. Minor deletion in the SANT 
domain shows reduced ability for binding histone tails, and results in Ada2 complexes 
that are inactive in HAT assays. In the case of nuclear corepressors such as NCOR and 
SMRT, the SANT domain is involved in the HDAC activity. These corepressors both 
contain two closely spaced SA T domains and are known to recruit HDAC to the target 
genes through interaction with unliganded receptors . NCOR and SMRT alone with the 
HDAC3 subunit is sufficient for active HDAC, and deletion of the amino SANT domain 
disrupts the binding ofHDAC3 to SMRT emphasizing the role of SANTin protein-
protein interactions. The mechanism by which this domain is responsible for activation of 
the catalytic unit ofthe HDAC is unclear. 
In the case ofhMIERl, there is no HAT or HDAC activity associated with the 
SANT domain. The SANT domain is required for association of hMIER I with the 
chromatin of its own promoter via Spl. The SANT domain, which does not bind the 
DNA directly, physically interacts with Spl and through interaction hMIERI represses 
Sp l driven transcription. As a result, the SANT domain ofhMIER 1 appears to repress 
transcription from its own promoter by a HDAC independent mechanism. 
IV The Proline Rich Region 
Another highly conserved motif found in hMIERI is a proline rich region denoted 
as PXXPP, where P represents the amino acid proline and X represents any other amino 
acid . In other proteins the binding of SRC homology 3 (SH3) domains has been shown 
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to be mediated by this proline rich motif (reviewed in Li, 2005). SH3 domains are a 
group of well characterized small interaction modules ubiquitously expressed in 
eukaryotes that mediate protein-protein interaction. These domains play important roles 
in mediation of many biological processes such as assembly of large multi-protein 
complexes, subcellular localization of components in signalling pathways, and regulation 
of enzym es via intramolecular interactions. 
The proline rich region in hMIERl may function as a recognition site for this 
family which provides numerous avenues by which it may play a role in cell signalling 
and development. For example, overexpression ofxMIERl in Xenopus development 
results in embryos with abnonnalities in both anterior and posterior structures (Tep li tsky 
eta/., 2000). Further studies revealed that only Proline 365 located in the consensus SH3 
binding motif was required for this effect on embryonic development. This demonstrates 
that xMIERl developmental effects are m ediated by the proline rich region. Since 
xMIERl and hMIER1 are highly conserved it also implies that hMIER1a may also have 
a functional SH3 binding motif within its proline rich region. F urther investigation of this 
domain in combination with the evidence from the previously discussed conserved 
regions may demonstrate a role for hMIER 1 in regulation of cell growth via protein-
protein interactions . 
V The LXXLL motif 
In the hMIERl a C tenninus, there is a conserved motif known as the LXXLL 
motif, where L is leucine and X is any amino acid. LXXLL motifs are found in many 
proteins that interact with nuclear hormone receptors and are required for the binding of 
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transcriptional regulators to the ligand binding domain in nuclear receptors (Heery et a!. , 
1997). Mutation ofthe hydrophobic residues around specific helices in the li gand 
binding domain disrupts ligand-dependent interaction of the LXXLL motif with the ER 
and its corresponding cofactors. Mutation of these residues also abolishes li gand-
independent (AF-2) function. The ability of nuclear receptor cofactors, such as SRC-1 , to 
bind in the presence of ligand is dependent upon an intact LXXLL motif. 
VI. uclear Locali zation Signal 
Studies with xMIERl identified a functional nuclear localization signal in the C-
terminal domain (Post eta!. , 2001). Analysis of the human isoforrns ofMIERl revealed 
that the hMIERl~ C terminus displays a high degree of similarity to that of the xMlERl 
Patemo et a/. ,2002). Transfection assays with NIH 3T3 cells revealed that hMIER 1 ~ was 
targeted exclusively to the nucleus while hMIERla remained cytoplasmic. This implies 
that alternative splicing ofhMIERla and hMIERl~ may provide functionally distinct 
roles within the cell. The lack of an NLS in hMIERla does not rule out the possibility of 
transport into the nucleus through binding to other proteins, such as to nuclear hormone 
receptors. 
1.5 Purpose of this Study 
The structure ofhMIER1 implies that it has a potential role as a transcription 
factor. Its acidic activation domain, ELM2, SANT and proline rich region also 
demonstrate that hMIERl is capable ofprotein-protein interaction. An LXXLL moti f in 
hMIER 1 a indicates that this protein can also interact with nuclear receptors such as the 
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ER. Previous studies in our lab have characterized hMIERl as a coregulator of the human 
ERa (Sa vicky eta!., unpublished). The purpose of this study was to further characterize 
the interaction of hMIER I with ERa and to investigate the interaction of hMIER I with 
the novel ubtype ER~. DNA binding assays were perfom1ed to determine if the 
interaction ofhMIERl with the ER subtypes affects the ability ofER to bind its 
consensus ERE. In order to provide functional insight, the effect ofhMIERl on ERE-
driven transcription in response to ERa and ER~ mediated signalling was investigated. 
Given the fact that hMIER 1 a has previously been shown to interact strongly with 
bothER subtypes in vitro, and given the presence of an LXXLL domain, it is 
hypothesized that the hMIERl a subtype will interact withER at its consensus ERE and 
have an effect on ER driven transcription. hMIERl ~also interacts with bothER subtypes 
in vitro, and due to differential structure hMIER 1 ~ may differ from hMIER 1 a in both 
physical and functional effects on the ER at its consensus ERE. Analysis of hMIER I 
interaction with the ERa and ER~ may provide insight for the role of this novel 
transcription factor in estrogen signalling and estrogen related diseases, such as breast 
cancer. 
Objective 1: To determine the effect of hMIERJ on the binding of ERa. and ER/3 to a 
consensus ERE in the absence and presence of ligand. 
Some transcriptional regulators affect transcription by enhancing or repressing the 
ability of the ER to bind DNA. Since hMIERl has previously been shown to interact with 
both ERa and ER~ in vitro, electrophoretic mobility shift assays (EMSAs) were 
performed to investigate whether hMIER l affected DNA binding of in vitro synthesized 
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ERa and ER~. 
Objective 2: To characterize the role of hMIERJ in RE-driven transcription in the 
absence of ligand 
The structure of hMIER 1 reveals characteristics of both a transcriptional activator 
and repressor. The functional effect ofhMIERl cannot be detem1ined in vitro, so 
hMIER I a, hMIER I~' ERa, and ER~ proteins were co-expressed in HEK 293 cells. Since 
ERa and ER~ are activated differently based on whether a ligand is present, the effect of 
hMTER 1 was first determined in the absence of ligand . Assays in which ERE was linked 
to a reporier gene were perfom1ed to detem1ine the ligand-independent effect of hMIER 1 
interaction on ERa and ER~ driven transcription. 
Objective 3: To characterize the role of hMIERJ in ERE-driven transcription in the 
presence of estrogen, DPN and PPT. 
In the presence of specific ligands ERa and ER~ respond differently based on differences 
in the ligand binding domain. Estrogen transactivates both of the receptor subtypes 
similarly, whereas specific SERMs such as PPT are specific for one ER subtype. The 
hMIERla, hMIERI ~,ERa and ER~ proteins were co-expressed in HEK 293 cells which 
were treated with specific ligands. Assays using an ERE linked to a reporter gene were 
used to determine the ligand-dependent effects of hMIERl on ER driven transcription . 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Plasmids and Constructs 
1. pCS3+MT; CS3+MT-hmierloJfJ 
pCS3+MT is a mammalian expression vector with 6 N-terminal repeats encoding 
the amino acid residues MEQKLISEEDLNE of the c-myc protein (gift from David 
Turner, University of Michigan). The expression vectors containing full length hmierl a 
or hmierlfJ (accession numbers A Yl24187 and AD51544 7, respectively) were 
engineered in our laboratory by Z. Ding. 
II . pGEX-4T-1; GST-hmierla, GST-hmierlfJ 
pGEX-4T -1 is a Glutathione S-transferase gene fusion vector for the expression, 
detection and purification of GST fusion proteins in bacteria (Pharmacia, Biotech). GST-
hmier 1 oJ(J constructs were engineered in our laboratory by Z.Ding. The appropriate 
isofom1 was cloned into the pGEX-4T -1 vector. 
111 pCMX, pCMX-mER oJ(J 
The mouse ERa was a gift from Dr. Christine Pratt (University of Ottawa; 
accession number NP _031982) and the mouse ER~ was a gift from Dr. John White 
(accession number U81451). Partial sequences were obtained to verify the identity of the 
received plasmids. 
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IV. 3XERE-TATAluc 
The 3XERE-TATAluc plasmid contains three copies of the vitellogenin estrogen 
response element (ERE) sequence (ggtcacagtgacc) preceding the luciferase gene in a 
mammalian expression vector pGI2-TATA. This plasmid was purchased from Addgene, 
Inc. 
V. pRSV ~gal 
The pRSV ~gal plasmid is a mammalian expression vector containing the~­
galactosidase gene (~gal) downstream of a rous sarcoma virus (RSV) promoter 
(Promega). This construct is commonly used for monitoring the transfection efficiency in 
mammalian cells. 
2. 1.2 Plasmid preparation and purification 
Prior to preparation of the plasmids XL Blue chemically competent cells 
(Stratagene Inc.) were transformed by adding approximately 1 ~g of DNA to 100 ~I of 
cells. The reaction was gently mixed with a pipette tip and incubated on ice for 30 
minutes . The reaction was then heat shocked at 42°C for 40 seconds and placed back on 
ice for 1-2 minutes. To the reaction was added 250~1 ofLuria broth (LB) medium (5 g 
peptone, 2.5 g yeast extract, 5 g NaCI, 500 ml dH20 ; autoclaved) was added and the 
culture was shaken at 37 °C for 60 minutes. After incubation 100 ~1 of the culture was 
plated on aLB ampicillin (5 g peptone 2.5 g yeast, 5 g NaCI, 7.5 g Agar, 500 ml dH20 ; 
autoclaved; 50 ~g/ml ampicillin) and incubated at 37°C overnight. The following day, 
one colony from each plate was selected and allowed to grow in a 150 ml LB medium 
with 50 ~g/ml ampicillin culture, shaking at 37 oc overnight. The following morning the 
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cultures were centrifuged at 3000xg to pellet the bacteria. At this point DNA purification 
was performed using the Nucleobond PC500 EF plasmid maxi prep kit (Clontech 
Laboratories Inc.) was can·ied out as per the manufacturer's instructions. 
2.2 GST Fusion Protein Production 
To produce GST fusion protein, approximately 10 ng ofthe pGEX-4Tl plasmid 
was added to 100 f..ll ofBL21 Codon Plus RP chemically competent cells (Stratagene) . 
The reaction was gently mixed with a pipette tip and incubated on ice for 30 minutes. The 
reaction was then heat shocked at 42°C for 40 seconds and placed back on ice for 1-2 
minutes. Then, 250 f..ll ofLB medium was added and the culture was shaken at 37 °C for 
60 minutes. After incubation 100 f..ll of the culture was plated on aLB ampici llin plate 
and incubated at 3 7°C overnight. The following day, one colony from each plate was 
selected and allowed to grow in a 5 ml LB medium with 50 j..lg/ml ampicillin culture, 
shaking at 37 °C overnight. The next morning, 1 ml of the culture was used to inoculate 
250 ml ofLB medium with 50 j..lg/ml ampici llin and allowed to grow at 37 °C, shaking, 
fo r approximately 3.5 hours. The optical density (OD) of the culture was measured at this 
time at 600 nm in a spectrophotometer (Beckman Du-64). Provided the culture had 
reached an OD of 0.6-0.8, 25 f..ll of IPTG (isopropyl-b-D-thiogalactopyranoside; 
Invitrogen) was added to induce protein production. The culture was then allowed to 
grow with shaking at 37 oc for an additional 3.5 hours. The culture was poured into a 250 
ml algene polypropylene bottle and centrifuged at 4000 rpm in a Sorval centrifuge for 
15 minutes. All of the supernatant was drained and the pellet was re-suspended in 5 ml 
of ice cold 1 X PBS. The re-suspended pellet was placed in a 50 ml falcon tube and 25 f..l l 
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of0.2 M phenylmethylsulfonyl fluoride (PMSF, Sigma) was added. Cells were then lysed 
by sonication on ice for 2 minutes in 30 second bursts with 10 second rest periods using a 
Sonic Dismembrator (Model 500, Fisher-Scientific). Following sonication, 500 ul of 10% 
Triton X-1 00 (Sigma) was added and the mixture was transferred to a 30 ml Corex glass 
tube. The sample was balanced to within 0.01 g and centrifuged at 4000xg in a Sorval 
RC-SB centrifuge for 15 minutes. The supernatant was aliquoted into clean labelled 1. 7 
ml tubes and placed at -80°C for storage. GST fusion protein expression levels and purity 
were checked by SDS polyacrylamide gel e lectrophoresis (SDS PAGE). 
2.3 In vitro Coupled Transcription-Translation 
In vitro translations were performed using the TnT® T7 Coupled Reticulocyte 
Lysate System (Promega). Each 50 ) ..d reaction mixture contained: 25 ) ..d TnT Rabbit 
Reticulocyte Lysate, 2 ~J.I TnT® Reaction Buffer, 1 111 amino acid mixture minus 
methionine, 1 ~J.l of Ribonuclease Inhibitor (RNA guard, Amersham Biosciences), 1 111 of 
T7 polymerase, 5 111 of 35S methionine. The appropriate volume ofDEPC water was 
added to make up a final vo lume of 50 111 per reaction. A master mix of these components 
was made up to the appropriate vo lume and distributed equally to all samples. ln order to 
perform both labelled and unlabeled reactions, the master mix was made up as described 
above and separated into two separate mixtures before the addition of 35S. The radiolabel 
was added to the labelled reaction mix, while an appropriate amount of amino acid 
mixture minus leucine was added to the unlabeled mixture. Both master mixtures were 
aliquoted for each sample, and 1 11g of the appropriate DNA was added to each reaction 
All samples were incubated together for 90 minutes at 30 °C. The samples were 
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consequently analyzed using SDS PAGE to determine ifthe proteins produced were the 
correct full length product, as is determined by the predicted molecular weight for that 
protein. Tricholoroacetic acid (TCA) precipitation was performed to detem1ine percent 
incorporation of radioactive label. 
2.3.1 Detennination of Incorporation of Radioactive label 
After completion of the in vitro transcription translation reaction , TCA 
precipitation assays were conducted to detennine the success of radioactive 
incorporation. For each reaction, 2 ~-tl of the translation product was bleached in 98 ~-tl of 
1 N NaOH, 2% H 20 2 in dH20), votiexed briefly and incubated at 37°C for I 0 minutes. 
Following the incubation 900 ~-tl of ice cold 25% TCN2% casamino acids (Merck) was 
added to precipitate the translation product. This mixture was incubated on ice for 30 
minutes. The precipitation product was then collected on Whatman filter paper (Fisher) 
under vacuum as follows: 1 ml of 5% TCA was filtered under vacuum; next 1 ml of 
sample and 1 ml of 5% TCA (used to wash the sample tube) were fi ltered under vacuum, 
followed by 2 washes of 3 ml of 5% TCA. Finally, 3 ml of l 00% acetone was added to 
dry the filter paper. To detem1ine 35S incorporation, the filter was placed in 
Biodegradable Counting Scintillant (Amersham) and analyzed in a Beckman S3801 
Scintillation Counter. 
2.4 Cell Culture 
Human embryonic kidney cells (HEK 293) were obtained from the American 
Tissue Culture Collection (ATCC). The cells were cultured in Dulbecco's Modified 
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Eagle's medium (DMEM, Invitrogen), with the addition of7.5% Calf Serum (CS; 
Invitrogen) and 2.5% Fetal Bovine Serum (FBS; Invitrogen). The cells were cultured in a 
3JCC incubator with 5% C02 
2.5 Transfections 
Approximately 18 hours prior to the transfection procedure, HEK 293 cells were 
seeded at a density of 5.0 x l 05 cells/well in 6 well plates (Coming Inc .). Cells were 
seeded in phenol red free (PRF) DMEM media with 10% charcoal stripped FBS. 
Approximately 1 hour prior to transfection, the supplemented media was aspirated and 
PRF media minus serum was added. Cells were transfected with the following plasmids 
in co-transfec ion experiments: 3x ERE-T ATA luc and ,Bgal along with either pCS3+MT, 
pCS3+MT -hmierl a, or pCS3+MT -hmier 1 ,8, and ERa or ER,B. Cells were transfected with 
a total amount of 1.9)..lg of plasmid DNA with 6)..ll of Plus reagent (Invitrogen) according 
to the manufacturer's protocol. Briefly, the 1.9 )..lg ofDNA was mixed with 6 111 of Plus 
reagent in the appropriate amount ofPRF medium (minus serum) and incubated at room 
temperature for 15 minutes. The mixture was then added to 6 111 ofLipofectamine reagent 
(Invitrogen) diluted in the appropriate amount ofPFR medium (minus serum) and 
incubated for an additional 15 minutes at room temperature. Additional PRF (minus 
serum) media was added to the samples to make up the final volume and 1 ml of the 
mixture was added to the cells in each well. The cells were incubated for 4 hours at 37°C, 
following which the PFR medium (minus serum) was replaced with PFR medium plus 
10% charcoal stripped FBS and incubated at 37°C for an additional 48 hours. 
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2.6 Reporter Assays 
2.6.1 Luciferase Reporter Assay 
HEK 293 cells were seeded in 6 well plates in PRF DMEM approximately 18 
hours prior to transfections. For the ERa or ERP homodimer experiments, cells were 
transiently transfected with 0.5 J..lg of3xERE-TATAiuc reporter plasmid, 0.2 J..lg ofpgal 
reporter plasmid, 0.4 J..lg of either ERa, ERP or CS3+MT, and 0.8 J..lg of either CS3+MT, 
pCS3+MThmier 1 a or pCS3+MThmier 1 fJ. Approximately 24 hours fo llowing 
transfection, cells were treated for an additional 24 hours with either 10-8 M 17 P-
estradiol (Estrogen) (Sigma-Aldrich), 10-8 M PPT (Sigma-Aldrich), 10-8 M DPN (Tocris) 
or an equivalent volume of vehicle as appropriate to each experiment. HEK 293 cel ls 
were harvested 48 hours after transfections as follows; the PFR DMEM was removed by 
aspiration, each well was washed with 1 ml lxPBS which was also aspirated, then 400 f..l l 
of l x Cell Lysis Buffer (Promega) was added to each well. Each well was scraped gently 
and cells were incubated with lys is buffer for 20 minutes on ice. The lysate was then 
transferred into clean labeled 1.7 ml centrifuge tubes and spun at 12000xg for 15-20 
seconds at room temperature. The supernatant was co llected into new 1. 7ml tubes. The 
lysate was either assayed immediately or stored at -80°C until further use. Luciferase 
assay substrate was removed from -80°C and allowed to thaw for a minimum of 30 
minutes before use. Luciferase assays were performed by mixing 10 f..ll of cell lysate with 
50 J..ll of luciferase assay substrate for 10 seconds. The sample was then quantified using a 
Monolight 2010 luminometer (Analytical Luminescence Laboratory). The relative 
luciferase units were recorded for each sample and later nonnalized according to 
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transfection efficacy (described below). Each experiment was perfom1ed three times in 
triplicate and statistical analysis using students t-test, p<0.01. 
2.6.2 ~-galactosidase Reporter Assay 
Beta-galactosidase Wgal) reporter assays were perf01med in order to correct the 
RLU according to the transfection efficiency of each sample. Thawed samples were 
vo11exed briefly to ensure thorough mixture of the lysate. 200 ~-tl of ~gal buffer [Z buffer 
(16.1 giL Na2HP04, 5.5 g/L NaH2P04, 0.75 giL KCl, and 0.246 g/L MgS04), 4 giL 
ortho-nitrophenyl-~-galactoside (ONPG), and 0.27% ~-metcaptoethanol (~-M-EtOH)] 
was added to labelled 1.7 ml tubes. At timed intervals 10 )ll of cell lysate was added to 
the appropriate tube and votexed for 1-2 seconds. A negative control sample containing 
cell lysis buffer instead of cell lysate was included for each assay. The samples were 
al lowed to incubate at room temperature for 2 minutes, at which point a yellow color 
began to develop, then 200 )ll of a stop buffer ( 1 M Iris pH 11) was added at timed 
intervals in the same sequence as the lysate. Once all reactions were stopped, the 200 ~Ll 
of each sample was loaded onto a 96 well plate. The plate was then read in a microplate 
spectrophotometer at a wavelength of 415 nm. The value for the sample containing cell 
lysis buffer alone was subtracted from all cell lysate samples to provide specific values. 
2. 7 Electrophoretic Mobility Shift Assays 
Electrophoretic mobility shift assays (EMSAs) were performed using a radio-
labelled vitel logenin consensus ERE (5' tcg age aaa gtc a~ cag tga cct gat caa t 3'). 
Five picomoles (pmol) of the double stranded DNA was incubated in a 25 )ll reaction 
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containing 25).lCi y-32P ATP and 10 units T4 polynucleotide kinase (Invitrogen) in IX 
forward reaction buffer (Invitrogen) at 37°C for 30 minutes. This T4 kinase enzyme 
transfers they-phosphate of ATP to the 5' end of the DNA, labelling the DNA with the 
32P. The DNA was then purified using an ethanol/sodium acetate overnight precipitation 
at -20 oc. The precipitation reaction contained 2.5!11 (1/10111 the original vo lume) of 
sodium acetate, 62.5 ).11100% EtOH (2.5x the original volume) and 2ul oftRNA 
( I Omg/ml). After 18-24 hours, labelled probe was centrifuged at 12000xg for 20 minutes 
the pellet was washed with 70% EtOH to remove excess free 32P, and centrifuged again at 
12000xg for an additional 15 minutes. The pellet was re-suspended in 40 )ll if dH20 and 
I 111 of this solution added to 3 ml Biodegradable Counting Scintillant (Amersham) was 
analyzed in a Beckman S3801 Scintillation counter to detem1ine 32P incorporation. Based 
on this, the probe was diluted to 100,000 cpm/).ll in dH20. For example if 1 ).ll of the re-
suspended probe was 300,000 cpm this means there was a total of approximately 
I ,200,000 cpm in total. The probe would be suspended in a final vo lume of 120 ).ll of 
dH20 , which requires adding an additional 80 ).ll of dH20 to the sample. 
For the EMSA reaction, a master mix was prepared such that each 20 111 reaction 
contained a final concentration of2 ).lg/).ll Poly(dl-dC), 5% glycerol, 85 g/ml bovine 
serum albumin (BSA), 50 mM HEPES, 4 mM Tris pH7.6, 1 mM dithiothreitol (OTT), 50 
mM KCI, 5 mM MgCI2, and 10 ).lM ZnS04 . A 100,000 cpm aliquot of labelled probe was 
incubated in this reaction mixture for 20 minutes at room temperature with 200 ng of 
GST, GST-hMIERla , or GST-hMIERlP and the unlabeled equivalent of l OO,OOOcpm 
ERa, ER~ or ERa/p TnT as measured by labelled TnTs of each protein performed in 
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tandem. The TnT samples were treated with either 10-8 M estrogen, PPT, DMSO or an 
equivalent volume of vehicle for 30 minutes prior to being added to the reaction. 
For antibody supershift assays, the EMSA reaction was perfom1ed as described 
above, however after the 20 minute incubation, the supershift reactions were incubated 
for an additional 30 minutes at room temperature with 2 ug of anti ERa (HC-20, Santa 
Cruz Biotechnology Inc .) or anti-ERP (Y19, Santa Cruz Biotechnology Inc.) polyclonal 
antiserum. The samples were then resolved by non-denaturing electrophoresis on 5% 
polyacrylamide gels made in TBE buffer. Each gel was allowed to run at 60V for 1 hour 
and 30 minutes in a 0.5x TBE buffer. The bands were fixed in a solution containing 20% 
methanol and 6% acetic acid, and dried by vacuum for 1 hour. The results were analyzed 
by autoradiography on Kodak biomax MS film. 
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3. Results 
3.1 The effect ofhMIERl on the binding ofER subtypes to a consensus ERE. 
Previous work has shown that both ERa and ERP interact with hMIER 1 in vitro, 
but the functional effects of this interaction are largely unknown. In this study, 
electrophoretic mobility shift assays (EMSAs) were perfonned to determine if hMIER 1 
interaction with the ER subtypes causes any disruption of ER binding to its consensus 
ERE. Also, because hMIERla contains an LXXLL motif not found in hMIERlP, it was 
investigated whether hMIERla and hMIERlP would differ in their interaction with the 
ER at its consensus ERE in the presence and absence of di fferent ligands. 
3. 1.1 in Vitro synthesized ERa. and ER(J specifically bind a consensus ERE 
Preliminary EMSAs were perfonned using the in vitro synthesized ERa and ER~ 
proteins to verify the formation ofthe appropriate homodimers. The dimers are identified 
based on the relative size of the bands as has been described in (Vanacker et a!. , 1999; 
Cowely et a!, 1997). The ERa protein is approximately 66 kDa, w hich is slightl y larger 
than the ER~ at 55 kDa. Therefore, the ERa homodimer-ERE complex is expected to 
migrate more slowly in the gel than the ERP homodimer-ERE complex ; the ER subtypes 
are indicated by arrows in Figure 3.1A. 
The ER homodimers were incubated with a 32P-label led ERE in the reaction 
buffer for 20 minutes at room temperature. The specific ERE-ER complexes were 
identifi ed by competition with a 40 fold excess of unlabelled ERE (Figure 3. 1 A, lanes 3 
and 5). To confinn that each specific band contained the expected ER subtype, parallel 
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Figure 3.1: ERa and ERP specifically bind the consensus ERE. 
A. An EMSA performed using 32P-labelled ERE probe showing the probe alone (lane 1) 
and specific ER subtype binding in the absence (lanes 2 & 4) and presence (lanes 3 & 5) 
of excess unlabelled ERE probe. B. The ERa homodimer (lane 1) was supershifted using 
an anti-ERa antibody (lane 2) (Santa Cruz, HC-20X). The ER~ homodimer (lane 3) was 
supershifted using an anti-ER~ antibody (lane 4) (Santa Cruz Y -19X) 
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reactions were performed and incubated with anti-ERa- or ERP-specific antibodies. 
Specific DNA-protein complexes containing ER will migrate tl1rough the polyacrylamide 
gel slower, a phenomenon known as a supershift. The supershifted ERa and ERP 
complexes are indicated in Figure 3.1 B, lanes 2 and 4. 
3. 1.2 The effect of hMJERJ on ERa ER-binding in the absence and presence of 
ligand. 
In order to investigate the effects hMIERla and hMIERlP have on the DNA 
binding ability of ERa, additional EMSAs were performed in the presence and absence of 
GST -hMIERl a and hMIER 1 p. EMS As were attempted using in vitro synthesized 
llMIER 1 protein; however the transcription-translation (TnT) reaction did not show an 
effect on ER-ERE binding. Since using TnTs ofhMIERl and ERin a 1:1 ratio would not 
dete1mine if excess hMIER 1 would disruptER-ERE interaction, another method of 
protein production had to be used to obtain more concentrated protein. Production of 
hMIER1 in the pGEX vector yielded large amounts ofGST-hMIERI fusion protein. The 
proteins could subsequently be purified using glutathione sepharose beads to determine 
the concentration of each GST-hMIERl fusion protein and a fixed amount of200ng 
could be consistently added to each reaction. 
To examine at the effects of hMIERl in the presence of estrogen, the ERa in vitro 
synthesized protein was treated with either 10-8M estrogen or an equivalent volume of 
vehicle for 30 minutes prior to incubation with GS1' alone, GST-hMIERI a , or GST-
hMIER I Panda 32P labelled ERE probe at room temperature. Incubation with GST alone 
acted as a control to show that the GST portion of the proteins would not disrupt the 
ability of ERa to bind its consensus ERE. 
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E2 + + + + 
Figure 3.2: GST fused hMIERla (GST-a) interferes with the ability of ERa to bind 
its consensus ERE in the presence of estrogen. 
Electrophoretic mobility shift assays (EMSAs) were used to investigate whether 
hMIERI a. or hMIERl ~ would affect the binding of ERa. to the ERE in the absence and 
presence of estrogen. In vitro translated ERa. was incubated with GST alone (lanes 1 &2), 
GST-hMIERla. (lanes 5&6), or GST-hMIERI~ (lanes 7&8). Unlabelled ERE probe was 
used as cold competitor to ensure the specificity of the ERa. band (lanes 3&4). The 
protein-DNA complexes were resolved through non-denaturing PAGE, and visualized by 
autoradiography. The position of ERa is indicated. Results were obtained from three 
independent experiments and shown is a representative autoradiograph. 
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As shown in Figure 3.2, ERa with GST alone shows no difference in DNA 
binding in the absence or presence of estrogen (lanes 1 and 2, respectively) and is 
successfu ll y competed out with unlabelled ERE probe (lanes 3 and 4). hMIER I a disrupt 
the ERa homodimer DNA binding either in the absence or presence of li gand (lanes 5 
and 6) . When compared to the control, there is little difference in the DNA binding of 
ERa with hMIERl ~ in the absence and presence of estrogen (lanes 7 and 8). 
The effects ofhMIERla, and hMIERl~ on the binding of ERa to the ERE in the 
presence of an ERa specific ligand, PPT, are shown in Figure 3.3. PPT has a 410 fold 
binding affinity preference for the ERa subtype and activates transcription through ERa 
only (Stauffer et al., 2000). While the ligand binding domains of the ER subtypes have 
only 55% amino acid identity, the specific residues that are involved with ligand binding 
are nearly identical. Studies indicate that the selectivity ofPPT lies in its differential 
preference for a specific leucine residue (Leu 384) in the ERa ligand binding domain 
where ER~ contains a methonine (Met 336). 
hMIER 1 a disrupts the DNA binding of ERa and this effect does not change in the 
presence ofPPT (lanes 5 and 6) . In contrast, hMIERl ~does not appear to inhibit the 
abi lity of ERa to bind its consensus ERE (lanes 7 and 8). 
Overall these results show that hMIERla, but not hMIERl~, disrupts the ability 
of ERa to bind its consensus ERE either in the presence or absence of li gand . 
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Figure 3.3: GST -hMIERla (GST -a) interferes with the ability of ERa to bind its 
consensus ERE in the presence of an ERa specific agonist, PPT. 
Electrophoretic mobility shift assays (EMSAs) were used to investigate whether 
hMIERla or hMIERl ~would affect the binding ofERa to the ERE in the absence and 
presence of PPT. In vitro translated ERa was incubated with GST alone (lanes 1 &2), 
GST-hMIERla (lanes 5&6), or GST-hMIERl~ (lanes 7&8). Unlabelled ERE probe was 
used as cold competitor to ensure the specificity of the ERa band (lanes 3&4). The 
protein-DNA complexes were resolved through non-denaturing PAGE, and visualized by 
autoradiography. The position of ERa is indicated. Results were obtained from three 
independent experiments and shown is a representative autoradiograph. 
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3. 1.3 The effect of hMIERJ on ERE binding of ER/3 in the absence and presence of 
ligand. 
EMSAs were also perfom1ed with in vitro translated ER~ protein in the presence 
or absence ofGST-hMIERla., and hMIERl~ (Figure 3.4). To determine the effect of 
hMI ERl a. and hMIERl~ on ER~ D A binding in the presence of estrogen, the in vitro 
translated ER~ was treated with 1 o·8 M estrogen or an equivalent volume of vehicle. The 
protein was then incubated with GST, GST-hMIERla., or GST-hMIERl ~·Incubation 
with GST alone acted as a control to show that the GST portion of the proteins would not 
disrupt the ability of ER~ to bind its consensus ERE. To ensure the ER~ band was 
specific, it was competed with unlabelled probe in the presence and absence of estrogen 
(Figure 3.4, lanes 3 and 4) . 
As shown in Figure 3.4, both hMIERI a. (lanes 5 and 6) and hMIERl ~(lanes 7 
and 8) appear to disrupt the ability of ER~ to bind D A in the presence and absence of 
estrogen. In the lanes treated with hMIERl a. or hMIERl~, it is interesting to note that an 
additional larger complex appears. The antibodies available for hMIER I did not function 
in a supershift, so it is not cetiain whether hMIERl interacts withER~ and supershifts the 
complex or if truly disrupts the DNA binding. In the latter, this larger complex may be a 
result of non-specific binding. 
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Figure 3.4: GST-hMIERla (GST-a) and GST-hMIERlP (GST-P) interfere with the 
ability of ERP to bind its consensus ERE in the presence of estrogen 
Electrophoretic mobility shift assays (EMSAs) were used to investigate whether 
hMIERla or hMIERIP would affect the binding ofERP to the ERE in the absence and 
presence of estrogen. In vitro translated ERP was incubated with GST alone (lanes 1 &2), 
GST-hMIERla (lanes 5&6), or GST-hMIER1 p (lanes 7&8). Unlabelled ERE probe was 
used as cold competitor to ensure the specificity of the ERP band (lanes 3&4). The 
protein-DNA complexes were resolved through non-denaturing PAGE, and visualized by 
autoradiography. The position ofERP is indicated. Results were obtained from three 
independent experiments and shown is a representative autoradiograph. 
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Figure 3.5: GST-hMIERla (GST-a) and GST-hMIERlp (GST-p) interfere with the 
ability of ERP to bind its consensus ERE in the presence of an ERP specific agonist, 
DPN. 
Electrophoretic mobility shift assays (EMS As) were used to investigate whether 
hMIERla or hMIERl~ would affect the binding ofER~ to the ERE in the absence and 
presence ofDPN. In vitro translated ER~ was incubated with GST alone (lanes 1&2), 
GST-hMIERla (lanes 5&6), or GST-hMIERI~ (lanes 7&8). Unlabelled ERE probe was 
used as cold competitor to ensure the specificity of the ER~ band (lanes 3&4). The 
protein-DNA complexes were resolved through non-denaturing PAGE, and visualized by 
autoradiography. The position ofER~ is indicated. Results were obtained from three 
independent experiments and shown is a representative autoradiograph 
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The effect ofhMJER1a and hMIER1~ on ER~ DNA binding was also examined 
in the presence of an ER~ specific agonist, DPN. The basis for the selectivity ofDPN for 
ER~ appears to be a result of the differences between specific amino acid residues in the 
ERa and ER~ ligand binding domain. TheN-terminal region of the ER~ ligand binding 
domain through helix 3 and a critical methoinine (Met336) are responsible for the 
specificity of DPN (Sun et al., 2003) . The ER~ protein was incubated with 1 o-s M DPN 
or an equivalent volume of ethanol prior to incubation with GST, GST-hMIERI a , or 
GST-hMIER1~. The ability ofER~ to bind DNA was inhibited by hMIERla and 
hMIERI ~in both the absence and presence of DPN (Figure 3.5, lanes 5-8). 
These results demonstrate that hMIERl a and hMlERl ~disrupted the ability of 
ER~ to bind its consensus ERE, regardless of the presence of ligand. This effect is likely 
mediated by a region common to both hMIER 1 a and hMIER 1 ~ as both isoforms have the 
same effect. However, with DPN there is no supershift complex similar to that seen with 
hMIER1 in the presence ofE2 (Figure 3.4, lanes 5-8). 
3.2 Effect of hMIER 1 on ERE-Driven Transcription in HEK 293 cells. 
It has previously been shown that hMIERla and hMIERl ~interact with ERa in 
vitro (Savicky, Masters dissertation). Through GST pulldown assays, it has also been 
shown the hMIERla and hMIERl~ interact withER~ in vitro (Fifield, Honours 
dissertation). Given that ERa and ER~ interact with hMIERI in vitro, and that the 
EMSAs showed that hMIERla and hMIERl~ are capable of affecting the DNA binding 
of the ERin vitro , it was important to detem1ine the functional effect of this interaction 
on ERE-driven transcription by the ER subtypes. Due to the fact that ERa and ER~ can 
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be activated in the absence of a ligand and that the cofactor recruitment may differ from 
that of ligand-dependent activation, assays were performed both in the absence and 
presence of ligand. Luciferase assays were performed using a 3xERE-TA TA-luciferase 
reporter construct, which contains 3 repeats of an ERE, a TATA box, and a luciferase 
gene downstream of the ERE. Estrogen receptors recognize and interact with the 
promoter region of genes that can·y one or more copies of a consensus ERE sequence 
(5 ' GGTCAnnnTGACC- 3') or variants ofthis sequence. 
Transcription of the ERE results in the production of the enzyme luciferase, that upon 
substrate binding will produce a light reaction that can be quantified as relative luciferase 
units (RLU). To determine the effect of hMIERl, two controls were in place, the first 
control contained only the 3xERE-TATA-Luc to determine ifthere was any endogenous 
ER driven expression. The second control contained only the 3xERE-TATA-Luc and the 
ER subtype in question. Since the CS3+MT vector used in these experiments contains 6 
-terminal repeats encoding the c-myc protein, this control ensured that any effects seen 
with hMIERla or hMIERl~ were not due to the myc tag itself. The ability ofhMIERia 
and hMIERl ~to regulate transcription can be analyzed by comparing the level of 
luciferase activity relative to that of ERa with the empty CS3+MT vector. A plasmid 
containing the reporter ~-galactosidase was also transfected into the cells for each assay 
as a measure of transfection efficiency. After raw luciferase readings were obtained for 
each lysate, ~gal assays were also perfom1ed on the samples to dete1mine the transfection 
efficacy. The raw luciferase data was normalized using the ~gal values to account for 
variability in transfection rates between samples. 
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Figure 3.6: hMIERla and hMIERlP enhance ERa ERE-driven transcription in the 
absence of ligand. 
HEK 293 cells were transfected with 0.5 11g of the 3xERE-TATA-Luc reported plasmid 
and 0.4 11g of ERa or ER~ and 0.8 11g of myc tagged empty vector, hMIER 1 a , or 
hMIERl ~- The control samples were transfected with the 3xERE-TA TA-luc and empty 
vector to control for activation by endogenous ERs. Cells were cultured in PRF DMEM 
in the absence of a ligand, and harvested 48 hours after transfection. The relative 
luciferase units (RLU) were determined and values normalized to transfection efficiency. 
Average values and standard error of 7 independent experiments are shown. The Myc 
empty vector of was compared to hMIERl -a and hMIERl-~, and significance evaluated 
by a standard t-test. 
* represents statistical significance p<0.05 
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3.2.1 The effect ofhMIERJ on ERE-driven transcription with ERa and ER[J in the 
absence of ligand. 
When compared to the control vector, both hMIERla (denoted myc-a) and 
hMIER l P (myc-P) significantly enhance ERa-activated transcription at the ERE in the 
absence of ligand (Figure 3.6). hMIERl p appears to be a more potent activator of ERa 
transcription than hMIERla at the ERE. With the ERp, neither hMIERla nor hMIER1P 
significantly affect transcription. The relative levels of activation with ERP reflect the 
well established fact that ERP typically is a weaker transcriptional activator than ERa in 
most cell systems (Pettersson and Gustafusson, 2001 ). While the ER subtypes are highly 
conserved in most regions, these results imply that hMIERla and hMIER1 p enhance 
transcription through a region of the ER specific to ERa, as it has no effect on ERP 
transcription . 
3.2.2 The effect of hMJERJ on ERE-driven transcription with ERa in the presence of 
ligand. 
To investigate the effects ofhMIERl in the presence of a ligand, luciferase assays 
were performed as described in section 3.1 with the ERa in the presence of 10·8 M 
estrogen or PPT. The effects of hMIERl a and hMIER 1 p were examined in comparison 
to the Myc-tagged empty vector control. A graph of the averages with standard error of 
three independent experiments is shown in Figure 3.7. 
It was found that hMIER 1 a and hMIER 1 p have no significant effect on ERa 
driven transcription at the ERE in the presence of estrogen. 
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Figure 3.7: hMIERla and hMIERlP do not significantly affect ERE-driven 
transcription with ERa in the presence of ligand. 
HEK 293 cells were transfected with 0.5 f..lg ofthe 3xERE-TATA-Luc reported plasmid 
and 0.4 f..lg of ERa, and 0.8 f..lg of myc tagged empty vector, hMIER 1 a , or hMIER 1 ~- The 
control samples were transfected with the 3xERE-TA TA-luc and empty vector to control 
for activation by endogenous ERs. Cells were cultured in PRF DMEM and treated with 
1o-8M estrogen, PPT or vehicle for 24 hours prior to harvesting. The relative luciferase 
units (RLU) were determined and values normalized to transfection efficiency. The 
averages and standard errors of 3 independent experiments are shown. The Myc empty 
vector was compared to hMIERla and hMIERl ~for each ligand and significance 
evaluated by a standard t-test. 
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To investigate the effect ofhMIERl on ERE-driven transcription in the presence 
of an ERa specific ligand, luciferase assays were also performed in the presence 1 o·8M 
PPT. In the presence of PPT, hMIERl a and hMIERl p have no significant effect on ERa 
driven transcription. These results indicate that hMIERla and hMIERl p do not affect 
ERa driven transcription in the presence of ligand. 
3.2.3 The effect of hMJERI on ERE-driven transcription with ER[J in the presence of 
ligand. 
Luciferase assays were performed as described in section 3.1 with the ERP in the 
presence of 1 o·8M estrogen or DPN. The effects of hMIERl a and hMIER 1 p were 
examined in comparison to the Myc-tagged empty vector control. A graph of the means 
with standard error of three independent experiments is shown in Figure 3.8. 
In the presence of estrogen, hMIER 1 a and hMIERl p have no effect on ERP 
driven transcription at the ERE. 
In the presence ofDPN, hMIERla and hMIERlP have no effect on ERP driven 
transcription. These results indicate that hMIERla and hMIERlP have no effect on ERP 
driven transcription in the presence of ligand. 
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Figure 3.8: hMIERla and hMIERlP do not significantly affect ERE-driven 
transcription with ERP in the presence of ligand. 
HEK 293 cells were transfected with 0.5 !J.g ofthe 3xERE-TATA-Luc reported plasmid 
and 0.4!J.g ofERP and 0.8 !J.g ofmyc tagged empty vector, hMIERla., or hMIERIP. The 
control samples were transfected with the 3xERE-TATA-luc and empty vector to control 
for activation by endogenous ERs. Cells were cultured in PRF DMEM and treated with 
1o-8M estrogen, DPN or vehicle for 24 hours prior to harvesting. The relative luciferase 
units (RLU) were determined and values normalized to transfection efficiency. The 
averages and standard error of 3 independent experiments are shown. The Myc empty 
vector was compared to hMIERla. and hMIERIP for each ligand and significance 
evaluated by a standard t-test. 
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4. Discussion 
Nuclear hormone receptors are essential for normal cell growth, differentiation 
and homeostasis. These proteins play an important role in cell proliferation as well as 
apoptosis, and excessive activation of their associated signalling pathways is implied in 
serious diseases such as cancer (reviewed in Singh and Kumar, 2005). Upon hormone 
binding, the receptors mediate the hormone effects through complex signalling that 
results in downstream gene expression or repression. However, in the case of hormone 
receptors such as ER, the pathways become especially complex as the receptor also 
exhibits hormone-independent signalling. The ER is capable of genomic (nuclear) and 
non-genomic (membrane and cytoplasmic) signalling which results in a wide range of 
ER-mediated effects. The genomic effects ofER involve receptor dimerization, nuclear 
localization, and binding of coregulatory complexes to estrogen response elements. This 
method of ER signalling is well characterized and may be ligand-dependent or 
independent. The majority of ligand-independent genomic signalling can be attributed to 
peptide growth factors such as, epidermal growth factor (EGF) or insulin-like growth 
factor 1 (IGF-1) (reviewed in Nilsson et aL., 2001). The non-genomic effects of ER are a 
mechanism through which estrogen can rapidly and transiently manifest its activity in a 
cell (Pietras and Marquez-Garban, 2007). These effects also account for l/3 of estrogen-
induced genes that lack functional estrogen response elements. In response to their 
respective li gands, nuclear hormone receptors initiate non genomic signal ling from the 
cell membrane or cytoplasm through interaction with numerous protein-kinase cascades. 
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The presence of an acidic activation, ELM2, and SANT domains, along with the 
proline-rich motif imply that hMIERl is capable of numerous types of protein-protein 
interactions. This in combination with the LXXLL motif in hMIER 1 a further suggests 
that hMIER 1 may play a role as a cofactor of nuclear hormone receptors such as ER. 
Previously hMIERl a has been characterized as an ERa cofactor (McCarthy et al., 2008, 
in press) and the purpose of this study was to further characterize hMIERI as an ER 
cofactor by investigating its interaction with and functional effects on ERa and ERP. 
4.1 In vitro interaction of hMIERl with both ERa and ERp. 
Previous work using GST pull down assays have demonstrated that both 
hMIERla and hMIERlP interacted with ERa and ERP in vitro (Fifield, Honours 
dissertation) . These results imply that while the LXXLL motif present in hMIERla may 
play a role, it is not fully responsible for the interaction of ER with hMIER 1. It is more 
likely that one of the domains in the common region ofhMIERla and hMIERlP is 
responsible for the interaction, as ERa and ERP bind both hMIERla and hMIERl p. 
In a previous study with ERa and hMIERl , it was determined that the SA T 
domain and the amino acids C-terminal to this domain were critical for ERa interaction 
(Savicky, Masters dissertation). The SANT domain has been associated with both HAT 
and HDAC activity in other proteins (Boyer et a/.,2004), therefore hMIERl has the 
potentia l for both transactivation and transrepression. Future investigation could include 
determining if this domain is involved with the interaction ofhMIERI with ERP. 
Studies to investigate whether ERB physically interacted with hMIER l a and 
hMIER I Pin vivo were attempted; however, due to lack of efficient ERP antibodies, the 
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results were inconclusive. Therefore, future studies would be required to characterize 
whether or not there is an interaction between endogenous hMIER 1 and endogenous 
ER~. 
4.2 Effect of hMIERl on ERE-binding of ERn and ERP 
Since previous studies have shown that hMIERla and hMIERl~ interact with the 
ERin vitro, and that hMIERl a also causes repression of ERa driven transcription at a 
promoter containing a consensus ERE, the effect of hMIERl on the ability of ER to bind 
its consensus ERE was studied. Electrophoretic mobility shi ft assays (EMSAs) were used 
to detem1ine the effect that hMIERl might have on ER-DNA binding at a consensus 
ERE. 
The present results showed that hMIERI a inhibited ERa and ER~ DNA binding 
in both the absence and presence of ligand . hMIERI ~also inhibited the D A binding of 
ER~ in the absence and presence of ligand, but has no effect on ERa-DNA binding. 
Taken together, these results implied that the interaction ofh.MIERla with the ER 
subtypes was distinctly different from that of hMIERl ~· 
It is interesting to note that the non-specific bands seen in lanes 3 and 4 of al l 
EMSA figures , were not competed out with unlabelled ERE, but appeared to be 
competed out in the presence ofGST-h.MIERl proteins. This effect was more prominent 
in some conditions compared to others, and was always a variab le result. The non-
specific bands could be caused by proteins in the reticulocyte lysate that non-specifica ll y 
bound to the ERE, but in the presence of a large protein such as h.MIER I , these proteins 
might simply bind preferentially to h.MIERl instead of the ERE sequence. It is not 
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believed that this is a significant result, but fut1her studies with controls containing the 
reticu locyte lysate and hMIERl could be perfom1ed to confirm this. 
In the EMSA withER~ and hMIERl in the absence or presence of estrogen 
(Figure 3.4, lanes 5-8) there is an additional band seen that appears to be larger than the 
ER-ERE complex. This band did not appear in the lanes withER~ alone, and therefore 
the specific ity cannot be detennined by looking at the lanes with excess probe 
competition (lanes 3 and 4). Unfortunately, the EMSA results did not provide much 
insight into the mechani sm by which hMIERl may be exerting its functional effects. In a 
cell, hMIERl may affect ER driven transcription in more than one way. It may bind the 
ER directly and sequester it away from its consensus ERE, leading to a decrease in 
transcription or it may bind the ER on the DNA and act as a transactivator or 
transrepressor. In the EMSAs, what appears as inhibition of DNA binding may be a result 
of something entire ly different. It is possible that hMIER 1 binds the ER and the labelled 
ERE which results in the supershifted band seen in the ER~ figure. In vitro synthesized 
ER~ has been shown to have a much lower affi nity for the ERE and a more diffuse 
binding pattem than that of ERa and longer exposures were required to get a c lear 
autorad iography picture. Perhaps with different exposures this complex may also show 
up with ERa. Or, ifhMIERI actually prevents the ER subtypes from binding the ERE, 
the larger complex may also have been a result of non-specific binding to some 
component of the reticulocyte lysate product or the GST fusion protein. Further studi es 
were attempted by using hMIERl antibodies to supershift both the ERa -ERE and ER~ ­
ERE complexes, but the antibodies available for hMIERl were not suitab le for supershi ft. 
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Additional studies could be performed to determine if this complex is present with ERa, 
and if this complex will be specifically competed with excess unlabelled ERE probe. 
It is clear from the EMSAs that ERa and ERP behave differently in their ability 
to bind DNA in the presence ofhMIERl. The one consistent effect seen across all 
experiments is the disruption of DNA binding by hMIERla with both receptor subtypes 
either in the absence or presence of ligand. 
4.3 Effect of hMIERl on ERE-driven transcription in the absence of ligand 
To determine if the EMSA results would reflect the effect of hMIERl in vivo 
functional assays measuring transcription from a consensus ERE were performed. The 
results from seven independent experiments in the absence of ligand revealed the 
hiMER I a and hMIER I p significantly enhanced ERE-driven transcription with the ERa 
homodimer (Figure 3.6). Neither hMIER 1 a nor hMIERl p had a significant effect on the 
RP homodimer in the absence of ligand. 
The functional difference between the transactivation ab lilities ofERa and ERP 
appear to be due to differences in the AF-1 domain, the ERa AF-1 domain autonomously 
initiates transcription when fused to a GAL4 DNA binding domain, but the ERP AF-1 
does not (reviewed in Pettersson and Gustafsson, 2001). This difference in the AF-l 
domain, which is responsible for ligand-independent interaction, results in differences in 
cofactor recn1itment and transcriptional activity in the absence of ligand for ERa and 
ERp. For example, ERP, in contrast to ERa, recruits SRC-1 in a ligand-independent 
manner, and transcriptional activation is dependent upon phosphorylation of critical 
serine residues in the NB domain. Perhaps through a similar mechanism hMIERl 
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appears to be recruited to ERa, but not ERP, as a coactivator in the absence of ligand . 
Future studies would include detem1ining which domain of the ER subtypes is 
responsible for interaction with hMIER 1. 
Since ERa and ERP have been shown to fonn heterodimers, and these 
heterodimers are capable of recruiting ER co factors and stimulating ERE-driven 
transcription, future studies could be perfonned to investigate the effects of hMIER 1 a 
and hMIER 1 p with the ERa/p heterodimer. Previous studies have shown that with an 
ERE-TAT A similar to the one used in these experiments, the ERa partner dictates the 
activity of the ERa/p heterodimer in ERE-dependent transcription (Li et al., 2004). 
Further studies by this group were performed with constructs containing enhancer 
promoter regions of estrogen responsive genes such as pS2. These studies revealed that 
when an ERP fusion receptor homodimer, which does not heterodimerize, is expressed in 
tandem with a fusion ERa homodimer in HeLa cells, increasing amounts of ERP resulted 
in a repression of transcription from the pS2 estrogen responsive promoters. However, 
when the ERa/P heterodimer was expressed with the ERa fus ion homodimer, it 
augmented the ERE-dependent activity, indicating it worked in synergy with the ERa 
partner. Based on the results of this previous study, further studies could be performed 
with hMIERl and the ER subtypes in the presence of more complex ERE promoters like 
pS2 in the absence or presence of ligand. 
The mechanism by which hMIERl may enhance ERa transcription in the absence 
of li gand is unclear. Prior to li gand binding, the ER is usually bound by chaperone 
complexes and ligand binding results in conformational change to release these 
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complexes and allow translocation to the nucleus, dimerization and cofactor recruitment 
(reviewed in Heldring et al., 2007). In the ligand-independent pathway phosphorylation 
of key residues in the ligand binding domain and the AF-1 domain in the absence of 
ligand result in coactivator recruitment and conformational change. Perhaps the un-
liganded conformation of ERa is more favourable to hMIERI binding, resulting in 
li gand-independent recruitment. However, it has a lready been described that hMIERI has 
the potential for many different protein-protein interactions. It is also possible that in the 
absence of ligand, hMIER1 may sequester corepressors away from the ER and enhance 
transcription by this mechanism. Further studies could be done to determine the complex 
in which hMIER1 is present on the ERE and whether hMIER1 itself directly interacts 
with the ER complex. It would also be of importance to repeat the previously described 
assays in di fferent cell types to determine if the cunent results are cell type specific. 
4.4 Effect of hMIERl on ERE-driven transcription in the presence of ligand 
To determine the effects ofh.MIERl in the ligand-dependent pathway, HEK 293 
cells were incubated w ith estrogen, PPT or DPN 24 hours prior to harvesting. The ER 
subtypes have similar affinity for estrogen, while PPT is an ERa specific agonist, and 
DPN is an ER~ specific agonist. The results from these experiments showed the 
hMlER I a had no ligand-dependent effects on ERa or ER~. 
The ligand binding domain of the ER subtypes is made of 12 a-helices denoted 
H1 -H 12. Upon ligand binding, H12 norma lly forms the AF-2 pocket by fo lding against 
H3, HS/6 and H II (Hall and McDonnell , 2005). The position ofH 12 is different based on 
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the structure and function ofthe ligand bound to the ER. Studies indicate that in 
antagonist binding H12 occupies the coactivator binding surface, blocking coactivator 
recruitment, whereas in agonist boundER, H 12 is repositioned to expose a hydrophobic 
groove to which coactivators can bind (Hall and McDonnell, 2005). In particular, the 
LXXLL motif in co factors provides a structural motif that wi II bind the hydrophobic 
groove in the ER ligand binding domain with high affinity. Most cofactors with LXXLL 
motifs are coactivators, but some co repressors have also been found to use this motif to 
bind the active ER and repress ER transcription. It is possible that the position of the HI2 
in the ligand binding domain plays some part in the differential binding of hMIERl in the 
absence or presence of ligand. 
The ligands estrogen, PPT and DPN, all bind to the ER ligand binding domain 
and use the AF-2 to determine specificity and function. However, these ligands do not 
bind in the same manner and they do not form identical conformations when bound to 
the ER. For example, the specificity ofPPT and DPN for ERa and ER~, respectively, is 
due to differences in a single amino acid residue H6 of the ligand binding pocket 
(Stauffer et al. 1999; Sun et al., 2003). While overall the ligand binding domain is poorly 
conserved between the receptors at 55% identity, the residues that line the ligand binding 
pocket and interact with ligand are nearly identical. The conformation change in the 
ligand bound state of the ER appears to be significant enough to block or suppress the 
effects ofhMIERla and hMIERl~ interaction. 
lt is also of imp011ance to note that the ligand treatments were for a 24 hour 
period , perhaps a more standard 48 hour ligand treatment would have produced an effect 
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with hMIER 1 and the ER subtypes. The 24 hour incubation period was chosen due to the 
fact that previous studies assayed reporter gene activity 24 hours after treatment with PPT 
and DPN (Sun et al., 2002; Sun et al., 2003; HarTington et al. 2003). The estrogen 
incubation was also 24 hours to provide comparable results, despite the fact that 
experiments in this laboratory have consistently been performed with a 48 hour estrogen 
treatment. Further studies should be performed using a time course ligand incubation of 
24, 48 , and 72 hours to detennine the cumulative effects of hMIER 1 on ERE-driven 
transcription in the presence of ligand. 
4.5 Conclusions and Future Studies 
hMlERl has been found to be differentially regulated in breast carcinoma tissues 
and cel ls lines, implying it may play a role in the normal growth and development of the 
breast (Paterno et a!., 1998). hMIER l is stmcturally similar to other well characterized 
transcriptional regulatory proteins known to be associated with the metastatic state such 
as the metastasis associated protein, MTAI. Like hMIER1, MTAl contains an ELM2 
domain, a SANT domain, acidic activation domains, and a proline rich region (Toh et al. , 
1995; Solari et al., 1999; Nicholson et al., 2003). MTA 1 or the MTA 1 related protein, 
MT A2, have been found to be involved in chromatin remodelling via the nucleosome 
remodelling histone deacetylase complex (NuRD). MTAl has been found to be over 
expressed in both breast carcinoma tissues and cell lines (Nicholson et al., 2003). 
Furthennore, MT A 1 has been found to be a potent corepressor of the ER via HDAC 
activity providing a potential mechanism by which it may be involved in the neoplastic 
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state (Mazumdar et al., 2001). Further investigation into the role that hMIER1 has on 
estrogen signalling and function may help clarify the role that hMIERl plays in estrogen 
related cancers. 
In this study the interaction of hMIER 1 with the ER and its functional effects was 
investigated. Characterization of the hMIERl-ER interaction could provide insight into 
the role that hMIER 1 may play in development of normal and abnormal breast tissue. 
The assays used to characterize the hMIERl-ER interaction in this study gave some 
conflicting results. In the absence of ligand, hMIER1a and hMIERlP enhance ERa 
transcription, presumably through the physical interaction represented in previous GST 
pulldown assays. Yet the interaction of hMIER 1 a and hMIER I P with the ERP in vitro is 
not functionally represented in vivo, as hMIER1 has no effect on ERP transcription. The 
in vitro EMSA results imply that, in both the presence and absence of li gand, hMIER I a 
disrupts ER-ERE DNA binding with bothER subtypes, and hMIERl B also disrupts ERP 
D A binding. These results indicate that hMIERl may repress transcription by 
interfering withER-ERE binding. However, this is not represented in vivo as hMIER1 a 
and hMIERl P enhance transcription in the absence of ligand but have no effect in the 
presence of li gand . 
As previous ly discussed, hMIERl could be causing a supershift of the ER band 
and not actually interfering with the ability ofER to bind its consensus ERE. However, if 
hMlERI does not supershift the ER complex and the result seen is actually due to a 
disruption ofD A binding, it is important to note that in vitro DNA binding can also be 
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very fastidious and slight changes that do not quite match the in vivo conditions could 
cause the ER to be blocked from binding the ERE. 
Also, in vitro synthesized proteins may lack important proteins for ER-DNA 
interaction. The ER-DNA complex is an intricate network of co factors and stabil izer 
proteins (reviewed in Petersson and Gustafsson, 2001 ). As previously discussed, the 
necessary co integrator proteins may be endogenously present in a cell system, but absent 
in the reticulocyte lysate used to synthesize proteins in vitro. Studies were attempted 
using nuclear extracts of breast cancer T47D cells desi gned with a tetracycline inducible 
system for hMIERI. However, due to difficulties optimizing the ER subtype expression 
and hMIER 1 induction they cou ld not be completed in this time frame. Future studi es 
should be performed using nuclear extracts specifically expressing the ER subtypes and 
hMIER 1 a or hMIER 1 ~ to better characterize the effects on DNA in the absence or 
presence of ligand in a more in vivo like system. 
Also, the in vivo effects of hMIER 1 may also be a result of its abil ity to sequester 
specific corepressors away from the ER-DNA complex, resulting in enhanced 
transcription without direct interaction withER. If hMIER 1 does not interact directly 
with the ER, the in vitro assays will be unable to accurately reflect the mechanism by 
which is exerts its effects on the ER. 
Another possible explanation for the discrepancies could involve the distinct C-
termini of hMIERla and hMIERl ~which indicate alternate functions and subcel lular 
localizations for the two isoforms. hMIERl a contains an LXXLL motif typical of 
cofactors of nuclear hormone receptor, in contrast hMIERl ~ contains a consensus nuclear 
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localization signal (NLS). It has been found that hMIERl ~is targeted to the nucleus in 
NIH 3T3 cells, whereas hMIERla, which lacks an NLS, remains cytoplasmic (Paterno et 
a!. , 2002).This does not exclude the possibility that hMIERla is transported to the 
nucleus through its interaction with other proteins such as nuclear hormone receptors. 
Since previous studies show that hMIERl ~may already be present in the nucleus, 
it may be more accessible to the ER. Ligand boundER subtypes may be in a 
conformation unfavourab le to hMIERI~ interaction and hMIERla translocation. Future 
studies involving immunocytochemistry and confocal microscopy are necessary to 
determine the subcellular localization ofh.MIERl in both the absence and presence of 
ligand in different cell types. Also, the determination of whether hMIER1 requires ER for 
translocation would be of importance. 
Taking all the results into consideration, this study successfully confirms that 
hMTER I interacts with both fo rms of the ERin vitro, and that it acts as a transactivator in 
of ERa-ERE driven transcription in the absence of ligand. This study helps characterize 
both hMIER 1 a and h.MIER I~ as novel co factors of ERa. Given that hMIER 1 is 
differentially expressed in breast cancer tissues and is similar to other known 
transcription factors involved in breast cancer, such as MT A proteins it is likely that 
h.MIER 1 may provide novel insight into estrogen-related cancers. Further studies with 
hMIERl a and h.MIERl~ may have significant implications in the development of novel 
treatments for estrogen related diseases such as breast cancer. 
69 
References 
Aasland, R.(1996). The SANT domain: a putative DNA-binding domain in the SWI-SNF 
and ADA complexes, the transcriptional co-repressors N-CoR and TFIIIB. Trends 
Biochem. Sci. 21,87-88 
Becker,W.M., Kleinsmith,L.J., and Hardin, J. (2003). The world of the cell. San Fransico, 
CA. Pearson Education Inc. 
Boyer, L.A. (2002). Essential role for the SANT domain in the functioning of multiple 
chromatin remodelling enzymes. Molec. Cel l. 10, 935-942 
Boyer, L.A. , Latek, R.R., and Peterson, C.L. (2004). The SANT domain: a unique 
histone-tail-binding molecule? at. Rev. Mol. Cell Bioi. 5 (2), 158-163 
Chang, E.C., Frasor, J., Komm, B., and Katzenellenbogen, B.S. (2006). Impact of 
estrogen receptor p on gene networks regulated by estrogen receptor a in breast cancer 
cells. Endocrinology 147, 4831-4842 
Cheng G. , Li, Y., Omoto, Y., Wang, Y., Berg, T., Nord, M., Vihko, P., Wamer, M., Piao, 
Y-S., and Gustafsson, J-A. (2004). Differential regulation of ERa and ERP in primate 
mammary g land. J. Clin. Endocr Metab. 90, 435-444 
Cowely, S.M., Hoare, S. , Mosselman S. , and Parker, M.G. (1997). Estrogen receptors a 
and P form heterodimers on DNA. J. Bioi. Chern. 272 (32), 19858-19862 
DeNardo,D.G. , Cuba, V.L. , Kim, H., Wu, K. , Lee, A.V., and Brown, P.H. (2007) 
Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. 
Mol. Cell. Endocriol. 277, 13-25 
Ding, X.F, Anderson, C.M. , Ma, H., Hong, H., Uht, R.M., Kushner, P.J. , and Stallcup, 
M .R. ( 1998). uclear Receptor-binding sites of coactivators glucocorticoid receptor I 
(GRIP!) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different 
binding specificities Mol. Endocrinol. 12, 302-313 
Ding, Z., Gi llespie, L.L, and Paterno, G.D. (2003) . Human MI-ER1 alpha and beta 
function as transcriptional repressors by recruitment of histone deacetylase 1 to their 
conserved ELM2 Domain. Mol Cell Bioi 23,250-258 
Ding, Z. Gi llespie, L.L, Mercer, F.C. , and Patemo, G.D . (2004) . The SANT domain of 
human MI-ER 1 interacts with Sp 1 to interfere with GC box recognition and repress 
transcription from its own promoter. J. Bioi. Chem. 279, 28009-28016 
70 
----- ----------- ------
Doisneau-Sixou, S .F., Sergio, C.M., Carrol, J.S., Hui,R., Musgrove, E.A., and 
Sutherland, R.L. (2003). Estrogen and antiestrogen regulation of cell cycle progression in 
breast cancer cells. Endocrine-Related Cancer 10, 179-186 
Escande, A., Pillon,A., Servant, ., Cravedi, J.P. , Larrea, F., Muhn, P., icholas, J.C., 
Cavailles, V., and Balaguer, P. (2006). Evaluation of1igand selectivity using reporter cell 
lines stably estrogen receptor alpha or beta. Biochem. Pharmacal. 71, 1459-1469 
Fifield, H .A. (2005). Interaction of a transcriptional regulatory factor, hMI-ERl, with the 
estrogen receptor p. Honors Dissertation. 
Forster, C., Makela, S., WatTi, A. , Kietz, S., Becker, D. , Hultenby, K., Warner, M., and 
Gustafsson, J-A. (2002). Involvement of estrogen receptor pin terminal di fferentiation of 
mammary gland epithelium. Proc. Natl. Acad. Sci. U.S.A. 99,15578-15583 
Gal-Yam, E.N., Saito, Y., Egger, G. , and Jones. P .A. (2007). Cancer epigenetics: 
modifications, screening and therapy. Almu. Rev. Med.59, 491-504 
Hall, J .M. and McDonnell, D.P. (2005). Coregulators in nuclear estrogen receptor action. 
Mol. Interventions 5(6), 343-357 
Hansein, B. , Eckner, R. , DiRenzo, J., Halachmi, S., Liu, H. , and Searcy, B., ( 1996). p300 
is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. USA. 
93,11540- 11545 
Hanstein, B., Djahansouzi, S. , Dall, P., Beckmann, M.W., and Bender, H.G. (2004). 
Insights into the molecular biology of the estrogen receptor define novel therapeutic 
targets for breast cancer. Eur. J. Endocrinol. 150, 243-255 
Harrington, W.R., Sheng, S. , Barnett, D.H. , Petz, L.N., Katzenellenbogen, J.A and 
Katzenellenbogen, B.S. (2003). Activities of estrogen receptor alpha- and beta-selective 
ligands at diverse estrogen responsive gene sites mediating transactivation or 
transrepression. Mol. Cell. Endocrinol. 206, 13-22 
Heery, D.M., Kalkhoven, E., Hoare,S. and Parker, M.G. (1997). A signature motif in 
transcriptional co-activators mediates binding to nuclear receptors. Nature 387,733-736 
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M. , 
Strom, A. , Treuter, E., Warner, M ., and Gustafsson, J.A. (2007). Estrogen receptors: how 
do they signal and what are their targets. Physio l. Rev. 87, 905-931 
71 
Hodawadekar, S.C., and Mam1orstein, R . (2007) Chemistry of acetyl transfer by histone 
modifying enzymes: structure, mechanism and implications for effector design. 
Oncogene 26, 5528-5540 
Hopp, T., W eiss, H. , Pan·a, 1. , Cui, Y. Osborne, C., and Fuqua,S., (2004). Low levels of 
estrogen receptor beta predict resistance to tamoxifen therapy in breast cancer. C linical 
Cancer R esearch 10, 7 490-7 499 
Katzenellenbogen, B .S. , and Katzenellenbogen, J.K. (2000). Review Estrogen receptor 
transcription and transactivation estrogen receptor alpha and estrogen receptor beta: 
regulation by selective estrogen receptor modulators and importance in breast cancer. 
Breast Cancer Res . 2, 335-344 
Kenney, N.J., Bowman, A., Korach, K.S ., Barret, J.C. , and Salomon D.S., (2003). Effect 
of exogenous epidermal-like growth factors on mammary gland development and 
differentiation in the estrogen receptor alpha knockout (ERKO) mouse. Breast Cancer 
Res. Treat. 79, 161-173 
Kim, K., Barhoumi,R . Burghardt, R. , and Safe.S. (2005). Analysis of estrogen receptor 
a-Sp 1 interactions in breast cancer cells by fluorescence resonance energy transfer. Mol. 
Endocriol. 19(4), 843-854 
Kuiper, G.G.J.M, Enmark, E ., Pelto-Huikko, M. , Nilsson, S. , and Gustafsson, J-A. 
(1996). Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. 
Nat!. Acad. Sci. U SA 93, 5925-5930 
Kushner, P.J., Agard, D .A., Greene, G .L., Scanlan, T.S, Shai u, A.K., Uht, R .M., and 
Webb, P. (2000). Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Bioi. 74 
3 11-317 
Lavinsky, R.M., Jepsen, K ., Heinzel, T. , Torchia, J. , Mullen, T. , Schiff, R. ,Del-rio, A.L, 
Ricote, M. , Ngo, S ., Gemsch, J., Hilsenbeck, S .G., Osborne, C.K., Glass, C.K. , 
Rosenfeld, M.G. , and Rose, D. W. (1998) Diverse signalling pathways modulate nuc lear 
receptor recruitment ofN-CoR and SMRT complexes. Proc. Nat!. Acad. Sci. USA. 95 , 
2920-2925 
Li, X., Huang, J. , Yi, P., Bambara, R.A. , Hilf, R. and Muyan, M. (2004). Single-chain 
estrogen eeceptors (ERs) reveal that the ERa/p heterodimer emulates functions of the 
ERa dimer in genomic estrogen signaling pathways. Mol. Cell. Bioi. 24( 17), 768 1-7694 
Li, S.S-C. (2005). Specificity and versatility ofSH3 and other proline-recognition 
domains: structura l basis and implications for cellular signal transduction. Biochem. 
1.390, 641-653 
72 
------ --- -
Matthews, J . and Gustafsson, J .A. (2003). Estrogen signalling: a subtle balance between 
ERa and ER~ . Mol. Interventions 3(5), 281-292 
Marino,M., Acconcia, F. and Ascenzi, P. (2005) Estrogen receptor signalling: Bases for 
drug actions. un·. Drug Targets Immune Endocr. Metabol. Disord. 5, 305-3 14 
Mazumdar, A., Wang, R.A. , Mishra S.K., Adam, L., Bagheri-Yarrnand, R. , Mandai, M., 
Yadlamudi ,R.K. , and Kumar, R. (2001) Transcriptional repression of oestrogen receptor 
by metastasis-associated protein 1 corepressor. at. Cell. Bioi. 3, 30-37 
McCarthy, P.L. (2008). Changes in subcellular localisation of MJ-ER I alpha, a novel 
oestrogen receptor-alpha interacting prote in, is associated with breast cancer progression. 
Br. J . Cancer 99( 4) 639-646 
McDonnell , D .P. (1999). The molecular pharmacology of SERMs. Trends Endocrinol. 
Metab . 10, 301-311 
Melcher, K. (2000). The strength of acidic activation domains correlates with their 
affinity for both transcriptional and non-transcriptional proteins. J . Mol. Bioi. 301, 1097-
111 2 
Meyers, M .J., Sun, J. , Carlson, K., Marriner, G.A. , Katzenellenbogen, B.S, and 
Katenellenbogen, J .A. (200 1). Estrogen receptor ~ potency-selective ligands : structure-
activity relationship studies of diarylpropioni triles and their acetylene and polar 
analogues. J. Med.Chem. 44, 4230-4251 
Moggs, J.G. and Orphanides, G. (2001). Estrogen receptors: orchestrators of pleiotropic 
cellular responses. EMBO reports 2(9), 775-78 1 
Nicolson, G.L., Nawa,A., Toh, Y., Taniguchi, S., Nishimori, K. , and Moustafa, A. 
(2003). Tumor metastasis associated human MTAJ gene and its MTA 1 protein product: 
role in epitheli al cancer cell invasion, proliferation and nuclear regu lation. Clin. Exp. 
Metastasis 20, 19-24 
ilsson, S. , Makela, S., Treuter,E., Tujague, M., Tomsen, J. Andersson, G. , Enmark, E., 
Pettersson, K., Warner, M. , and Gustafsson, J. (2001 ). M echanisms of Estrogen Action . 
Physiol. Rev. 81, 1535- 1565 
Pace, P. , Taylor, J. , Suntharalingam, S., Coombes, R.C., and Ali , S. (1997) . Human 
estrogen receptor~ binds DNA in a manner similar to and dimerize with estrogen 
receptor a. J . Bioi. Chern. 272 (41), 25832-25838 
73 
Patemo, G.D., Li, Y., Luchmann, H.A., Ryan, P.J. , and Gillespie, L.L. (1997) . cO A 
cloning of a novel , developmentally regulated immediate early gene activated by 
fibroblast growth factor and encoding a nuclear protein. J. Bioi. Chern . 10, 25591-25595 
Patemo, G.D, Mercer, C., Chayter, J.L. , Yang, X., Robb, J.D., and Gillespie, L.L. (1998). 
Molecular cloning ofhuman erl eDNA and its differential expression in breast tumours 
and tumor-derived cell lines. Gene 222, 77-82 
Paterno, G .D ., Ding, Z . Lew, Y., Nash, G.W ., Mercer, C.F. , and Gillespie, L.L. (2002). 
Genomic organization of the human mi-erl gene and characterization of alternatively 
spliced isofonns: regulated use of a facultative intron determines subcellular localization. 
Gene 295, 79-85 
Pettersson, K., and Gustafsson, J.A. (2001). Role of estrogen receptor beta in estrogen 
action. Annu. Rev. Physiol. 63, 165-192 
Pietras,R.J., and Marquez-Garban, D.C. (2007). Membrane associated estrogen receptor 
signalling pathways in human cancers. Clin. Cancer. Res. 13(16) 4672-4676 
Post, J., Gillespie, LL. and Patemo, G.D. (200 1). uclear locali zation signals in the 
Xenopus FGF embryonic early reponse 1 protein. FEBS Lett. 502, 41-45 
Roger, P ., Sahla, M.E., Makela, S., Gustafsson, J-A. , Baldet, P ., and Rochefort, H. 
(2001) . Decreased expression of estrogen receptor p protein in proliferative preinvasive 
mammary tumours. Cancer Res. 61, 2537-2541 
Safe, S.( 2001). Transcriptional activation of genes by 17 beta-estradiol through estrogen 
receptor-Sp 1 interactions. Vitam. Horm. 62, 231-252 
Savicky, M.W. (2004) Characterization ofhuman mesodem1 induction-early response 1 
(hMI-ER 1) as a nuclear hormone receptor cofactor. Masters of Science, Thesis. 
Saville, B., Wormke, M ., Wang, F., guyen, T. , Enmark, E., Kuiper, G. , Gustafsson, 
J.A. , and Safe, S. (2000). Ligand-, cell-, and estrogen receptor subtype (alphafbeta)-
dependent activation of GC-rich (Sp 1) promoter regions. J . Bioi. Chern. 275(8), 5379-
5387 
Singh, R.R. and Kumar, R. (2005). Steroid hormone receptor signalling in tumorigenesis. 
J. Cell. Biochem. 96, 490-505. 
Solari, F., Bateman, A., and Ahringer J. (1999). The Caenorhabditis elegans genes egl-
2 7 and egr-1 are similar to MT A 1, a member of a chromatin regulatory complex, and are 
redundantly required for embryonic patterning. Development 126, 2483-2494 
74 
Smith, C.L., Nawaz,Z. and O'Malley, B .W. (1997).Coactivator and corepressors 
regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-
hydroxtamoxifen. Mol. Endocrinol. 11(6), 657-666 
Stauffer, S.R., Coletta, C.J., Tedesco, R. , Nishiguchi, G. , Carlson, K., Sun, J. , 
Katzenellenbogen, B.S and Katzenellenbogen, J.A. (2000). Pyrazole ligands: structure-
affinity /activity relationships and estrogen receptor-a-selective agonists. J. Med . Chem. 
43, 4934-4947 
Struhl , K. ( 1987). Promoters, activator proteins, and the mechanism of transcriptional 
initiation in yeast. Cell 49, 295-297 
Suen, C. ., Berrodin, T.J., Mastroeni , R ., Cheskis, B.J., Lyttle, C.R. and Frail , D.E. 
( 1998) A transcriptional coactivator, steroid receptor coactivator-3 , selectively augments 
steroid receptor transcriptional activity. J. Bioi. Chem. 273(42), 27645-27653 
Sun, J. , Huang, Y.R., HarTington,W.R. , Sheng, S. , Katzenellenbogen, J.A, and 
Katzenellenbogen, B.S. (2002). Antagonists selective for estrogen receptor alpha. 
Endocrinology 143(3), 941 -947 
Sun, J. , Baudry, J. , Katzenellenbogen, J.A, and Katzenellenbogen, B.S. (2003). 
Molecular basis for the subtype discrimination of the estrogen receptor-~-selective 
li gand, diarylpropionitrile. Mol. Endocrinol. 17(2), 247-258 
Teplitsky Y., Patemo, G.D. and Gillespie, L.L. (2003). Proline365 is a critical residue for 
the activity ofXMI-ER1 in Xenopus embryonic development. Biochem. Biophys. Res. 
Commun. 308, 679-683 
Toh,Y., Pencil , S.D. and icolson, G.L. (1994) A novel candidate metastasis associated 
gene, mtal , differentially expressed in highly metastatic mammary adenocarcinoma cell 
lines. J. Bioi. Chem 269(37), 22958-22963 
Vanacker, J.M., Pettersson, K, Gustafsson, J.A, and Laudet,V. (1999). Transcriptional 
targets shared by estrogen related receptors (ERRs) and estrogen receptor (ER) a, but not 
by ER~. The EMBO J 18(15), 4270-4279 
Wang, L., Rajan, H ., Pitman, J.L.,McKeown, M., and Tsai, C.C. (2006). Histone 
deacetylase-associating Atrophin proteins are nuclear receptor corepressors. Genes Dev. 
20, 525-530 
Webb,P ., Valentine, C., Nguyen, P ., Price, R.H., Marimuthu, A. , West, B.L. , Baxter, J.D. 
and Kushner, P.J. (2003) . ER~ binds N-CoR in the presence of estrogens via an LXXLL-
Ii ke motif in theN-CoR C-tenninus. Nucl. Recept. 1:4 
75 
Williams,C. , Edvardsson, K., Lewandowski, S.A., Strom, A. and Gustafsson, J.A. (2007). 
A genome wide study of the repressive effects of estrogen receptor beta on estrogen 
receptor alpha signall ing in breast cancer cells. Oncogene 1-14 
76 




